1
|
Cui TT, Huang JX, Ning BL, Mu F, Chen HY, Xing TY, Li H, Wang N. DNA methylation promotes the expression of PPARγ transcript 1 at least in part by preventing NRF1 binding to the promoter P1 of chicken PPARγ gene. Poult Sci 2024; 103:103559. [PMID: 38430780 PMCID: PMC10912915 DOI: 10.1016/j.psj.2024.103559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 12/16/2023] [Accepted: 02/12/2024] [Indexed: 03/05/2024] Open
Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) is a master regulator of adipogenesis. Our previous study revealed that chicken PPARγ has 3 alternative promoters named as P1, P2, and P3, and the DNA methylation of promoter P3 was negatively associated with PPARγ mRNA expression in abdominal adipose tissue (AAT). However, the methylation status of promoters P1 and P2 is unclear. Here we assessed promoter P1 methylation status in AAT of Northeast Agricultural University broiler lines divergently selected for abdominal fat content (NEAUHLF). The results showed that promoter P1 methylation differed in AAT between the lean and fat lines of NEAUHLF at 7 wk of age (p < 0.05), and AAT expression of PPARγ transcript 1 (PPARγ1), which was derived from the promoter P1, was greatly higher in fat line than in lean line at 2 and 7 wk of age. The results of the correlation analysis showed that P1 methylation was positively correlated with PPARγ1 expression at 7 wk of age (Pearson's r = 0.356, p = 0.0242), suggesting P1 methylation promotes PPARγ1 expression. To explore the underlying molecular mechanism of P1 methylation on PPARγ1 expression, bioinformatics analysis, dual-luciferase reporter assay, pyrosequencing, and electrophoresis mobility shift assay (EMSA) were performed. The results showed that transcription factor NRF1 repressed the promoter activity of the unmethylated P1, but not the methylated P1. Of all the 4 CpGs (CpG48, CpG49, CpG50, and CpG51), which reside within or nearby the NRF1 binding sites of the P1, only CpG49 methylation in AAT was remarkably higher in the fat line than in lean line at 7 wk of age (3.18 to 0.57, p < 0.05), and CpG49 methylation was positively correlated with PPARγ1 expression (Pearson's r = 0.3716, p = 0.0432). Furthermore, EMSA showed that CpG49 methylation reduced the binding of NRF1 to the P1. Taken together, our findings illustrate that P1 methylation promotes PPARγ1 expression at least in part by preventing NRF1 from binding to the promoter P1.
Collapse
Affiliation(s)
- T T Cui
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; College of Life Science and Agriculture Forestry, Qiqihar University, Qiqihar, 161006, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - J X Huang
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - B L Ning
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - F Mu
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - H Y Chen
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - T Y Xing
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - H Li
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China
| | - N Wang
- College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Chicken Genetics and Breeding, Ministry of Agriculture and Rural Affairs; Key Laboratory of Animal Genetics, Breeding and Reproduction, Education Department of Heilongjiang Province, Harbin 150030, China.
| |
Collapse
|
2
|
Shen N, Xu T, Huang S, Mu F, Li J. Expert-Guided Knowledge Distillation for Semi-Supervised Vessel Segmentation. IEEE J Biomed Health Inform 2023; 27:5542-5553. [PMID: 37669209 DOI: 10.1109/jbhi.2023.3312338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
Abstract
In medical image analysis, blood vessel segmentation is of considerable clinical value for diagnosis and surgery. The predicaments of complex vascular structures obstruct the development of the field. Despite many algorithms have emerged to get off the tight corners, they rely excessively on careful annotations for tubular vessel extraction. A practical solution is to excavate the feature information distribution from unlabeled data. This work proposes a novel semi-supervised vessel segmentation framework, named EXP-Net, to navigate through finite annotations. Based on the training mechanism of the Mean Teacher model, we innovatively engage an expert network in EXP-Net to enhance knowledge distillation. The expert network comprises knowledge and connectivity enhancement modules, which are respectively in charge of modeling feature relationships from global and detailed perspectives. In particular, the knowledge enhancement module leverages the vision transformer to highlight the long-range dependencies among multi-level token components; the connectivity enhancement module maximizes the properties of topology and geometry by skeletonizing the vessel in a non-parametric manner. The key components are dedicated to the conditions of weak vessel connectivity and poor pixel contrast. Extensive evaluations show that our EXP-Net achieves state-of-the-art performance on subcutaneous vessel, retinal vessel, and coronary artery segmentations.
Collapse
|
3
|
Shen N, Xu T, Bian Z, Huang S, Mu F, Huang B, Xiao Y, Li J. SCANet: A Unified Semi-Supervised Learning Framework for Vessel Segmentation. IEEE Trans Med Imaging 2023; 42:2476-2489. [PMID: 35862338 DOI: 10.1109/tmi.2022.3193150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Automatic subcutaneous vessel imaging with near-infrared (NIR) optical apparatus can promote the accuracy of locating blood vessels, thus significantly contributing to clinical venipuncture research. Though deep learning models have achieved remarkable success in medical image segmentation, they still struggle in the subfield of subcutaneous vessel segmentation due to the scarcity and low-quality of annotated data. To relieve it, this work presents a novel semi-supervised learning framework, SCANet, that achieves accurate vessel segmentation through an alternate training strategy. The SCANet is composed of a multi-scale recurrent neural network that embeds coarse-to-fine features and two auxiliary branches, a consistency decoder and an adversarial learning branch, responsible for strengthening fine-grained details and eliminating differences between ground-truths and predictions, respectively. Equipped with a novel semi-supervised alternate training strategy, the three components work collaboratively, enabling SCANet to accurately segment vessel regions with only a handful of labeled data and abounding unlabeled data. Moreover, to mitigate the shortage of annotated data in this field, we provide a new subcutaneous vessel dataset, VESSEL-NIR. Extensive experiments on a wide variety of tasks, including the segmentation of subcutaneous vessels, retinal vessels, and skin lesions, well demonstrate the superiority and generality of our approach.
Collapse
|
4
|
Liang Y, Xu Q, Liu S, Li J, Wang F, Li Z, Liao L, Lu Y, Li Y, Mu F, Sun HX, Zhu L. Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells. Front Immunol 2022; 13:939940. [PMID: 35928827 PMCID: PMC9343810 DOI: 10.3389/fimmu.2022.939940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Accepted: 06/21/2022] [Indexed: 11/19/2022] Open
Abstract
T cell receptor-engineered T cells (TCR-Ts) have emerged as potent cancer immunotherapies. While most research focused on classical cytotoxic CD8+ T cells, the application of CD4+ T cells in adoptive T cell therapy has gained much interest recently. However, the cytotoxic mechanisms of CD4+ TCR-Ts have not been fully revealed. In this study, we obtained an MHC class I-restricted MART-127-35-specific TCR sequence based on the single-cell V(D)J sequencing technology, and constructed MART-127-35-specific CD4+ TCR-Ts and CD8+ TCR-Ts. The antitumor effects of CD4+ TCR-Ts were comparable to those of CD8+ TCR-Ts in vitro and in vivo. To delineate the killing mechanisms of cytotoxic CD4+ TCR-Ts, we performed single-cell RNA sequencing and found that classical granule-dependent and independent cytolytic pathways were commonly used in CD4+ and CD8+ TCR-Ts, while high expression of LTA and various costimulatory receptors were unique features for cytotoxic CD4+ TCR-Ts. Further signaling pathway analysis revealed that transcription factors Runx3 and Blimp1/Tbx21 were crucial for the development and killing function of cytotoxic CD4+ T cells. Taken together, we report the antitumor effects and multifaceted killing mechanisms of CD4+ TCR-Ts, and also indicate that MHC class I-restricted CD4+ TCR-Ts could serve as potential adoptive T cell therapies.
Collapse
Affiliation(s)
- Yanling Liang
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Qumiao Xu
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
- *Correspondence: Qumiao Xu, ; Feng Mu, ; Hai-Xi Sun, ; Linnan Zhu,
| | - Songming Liu
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Jie Li
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Fei Wang
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Ziyi Li
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Lijuan Liao
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Yuting Lu
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Yijian Li
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
| | - Feng Mu
- Beijing Genomics Institute (BGI), Shenzhen, China
- *Correspondence: Qumiao Xu, ; Feng Mu, ; Hai-Xi Sun, ; Linnan Zhu,
| | - Hai-Xi Sun
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
- Beijing Genomics Institute (BGI)-Beijing, Beijing, China
- *Correspondence: Qumiao Xu, ; Feng Mu, ; Hai-Xi Sun, ; Linnan Zhu,
| | - Linnan Zhu
- Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
- Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China
- Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China
- *Correspondence: Qumiao Xu, ; Feng Mu, ; Hai-Xi Sun, ; Linnan Zhu,
| |
Collapse
|
5
|
Xiang H, Zhang L, Bu F, Guan X, Chen L, Zhang H, Zhao Y, Chen H, Zhang W, Li Y, Lee LJ, Mei Z, Rao Y, Gu Y, Hou Y, Mu F, Dong X. A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources. Cancers (Basel) 2022; 14:cancers14123016. [PMID: 35740681 PMCID: PMC9220843 DOI: 10.3390/cancers14123016] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Revised: 06/09/2022] [Accepted: 06/13/2022] [Indexed: 11/16/2022] Open
Abstract
Tumor-specific antigens can activate T cell-based antitumor immune responses and are ideal targets for cancer immunotherapy. However, their identification is still challenging. Although mass spectrometry can directly identify human leukocyte antigen (HLA) binding peptides in tumor cells, it focuses on tumor-specific antigens derived from annotated protein-coding regions constituting only 1.5% of the genome. We developed a novel proteogenomic integration strategy to expand the breadth of tumor-specific epitopes derived from all genomic regions. Using the colorectal cancer cell line HCT116 as a model, we accurately identified 10,737 HLA-presented peptides, 1293 of which were non-canonical peptides that traditional database searches could not identify. Moreover, we found eight tumor neo-epitopes derived from somatic mutations, four of which were not previously reported. Our findings suggest that this new proteogenomic approach holds great promise for increasing the number of tumor-specific antigen candidates, potentially enlarging the tumor target pool and improving cancer immunotherapy.
Collapse
Affiliation(s)
- Haitao Xiang
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China; (H.X.); (X.G.); (W.Z.); (Y.L.)
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Le Zhang
- BGI-GenoImmune, BGI-Shenzhen, Shenzhen 518083, China; (L.Z.); (L.J.L.)
| | - Fanyu Bu
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Xiangyu Guan
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China; (H.X.); (X.G.); (W.Z.); (Y.L.)
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Lei Chen
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Haibo Zhang
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Yuntong Zhao
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Huanyi Chen
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Weicong Zhang
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China; (H.X.); (X.G.); (W.Z.); (Y.L.)
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
| | - Yijian Li
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China; (H.X.); (X.G.); (W.Z.); (Y.L.)
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
- Guangdong Provincial Key Laboratory of Human Disease Genomics, Shenzhen Key Laboratory of Genomics, Shenzhen 518083, China
| | - Leo Jingyu Lee
- BGI-GenoImmune, BGI-Shenzhen, Shenzhen 518083, China; (L.Z.); (L.J.L.)
| | - Zhanlong Mei
- BGI, Shenzhen 518083, China; (Z.M.); (Y.R.); (Y.H.)
| | - Yuan Rao
- BGI, Shenzhen 518083, China; (Z.M.); (Y.R.); (Y.H.)
| | - Ying Gu
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
- Guangdong Provincial Key Laboratory of Genome Read and Write, Shenzhen 518120, China
| | - Yong Hou
- BGI, Shenzhen 518083, China; (Z.M.); (Y.R.); (Y.H.)
| | - Feng Mu
- BGI, Shenzhen 518083, China; (Z.M.); (Y.R.); (Y.H.)
- Correspondence: (F.M.); (X.D.)
| | - Xuan Dong
- BGI-Shenzhen, Shenzhen 518103, China; (F.B.); (L.C.); (H.Z.); (Y.Z.); (H.C.); (Y.G.)
- Guangdong Provincial Key Laboratory of Human Disease Genomics, Shenzhen Key Laboratory of Genomics, Shenzhen 518083, China
- Correspondence: (F.M.); (X.D.)
| |
Collapse
|
6
|
Chen A, Liao S, Cheng M, Ma K, Wu L, Lai Y, Qiu X, Yang J, Xu J, Hao S, Wang X, Lu H, Chen X, Liu X, Huang X, Li Z, Hong Y, Jiang Y, Peng J, Liu S, Shen M, Liu C, Li Q, Yuan Y, Wei X, Zheng H, Feng W, Wang Z, Liu Y, Wang Z, Yang Y, Xiang H, Han L, Qin B, Guo P, Lai G, Muñoz-Cánoves P, Maxwell PH, Thiery JP, Wu QF, Zhao F, Chen B, Li M, Dai X, Wang S, Kuang H, Hui J, Wang L, Fei JF, Wang O, Wei X, Lu H, Wang B, Liu S, Gu Y, Ni M, Zhang W, Mu F, Yin Y, Yang H, Lisby M, Cornall RJ, Mulder J, Uhlén M, Esteban MA, Li Y, Liu L, Xu X, Wang J. Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays. Cell 2022; 185:1777-1792.e21. [PMID: 35512705 DOI: 10.1016/j.cell.2022.04.003] [Citation(s) in RCA: 313] [Impact Index Per Article: 156.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 01/24/2022] [Accepted: 04/01/2022] [Indexed: 10/18/2022]
Abstract
Spatially resolved transcriptomic technologies are promising tools to study complex biological processes such as mammalian embryogenesis. However, the imbalance between resolution, gene capture, and field of view of current methodologies precludes their systematic application to analyze relatively large and three-dimensional mid- and late-gestation embryos. Here, we combined DNA nanoball (DNB)-patterned arrays and in situ RNA capture to create spatial enhanced resolution omics-sequencing (Stereo-seq). We applied Stereo-seq to generate the mouse organogenesis spatiotemporal transcriptomic atlas (MOSTA), which maps with single-cell resolution and high sensitivity the kinetics and directionality of transcriptional variation during mouse organogenesis. We used this information to gain insight into the molecular basis of spatial cell heterogeneity and cell fate specification in developing tissues such as the dorsal midbrain. Our panoramic atlas will facilitate in-depth investigation of longstanding questions concerning normal and abnormal mammalian development.
Collapse
Affiliation(s)
- Ao Chen
- BGI-Shenzhen, Shenzhen 518103, China; Department of Biology, University of Copenhagen, Copenhagen 2200, Denmark
| | - Sha Liao
- BGI-Shenzhen, Shenzhen 518103, China
| | - Mengnan Cheng
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | | | - Liang Wu
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China; Shenzhen Key Laboratory of Single-Cell Omics, BGI-Shenzhen, Shenzhen 518120, China
| | - Yiwei Lai
- BGI-Shenzhen, Shenzhen 518103, China; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Xiaojie Qiu
- Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jin Yang
- MGI, BGI-Shenzhen, Shenzhen 518083, China
| | - Jiangshan Xu
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Shijie Hao
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Xin Wang
- BGI-Shenzhen, Shenzhen 518103, China
| | | | - Xi Chen
- BGI-Shenzhen, Shenzhen 518103, China
| | - Xing Liu
- BGI-Shenzhen, Shenzhen 518103, China
| | - Xin Huang
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Zhao Li
- BGI-Shenzhen, Shenzhen 518103, China
| | - Yan Hong
- BGI-Shenzhen, Shenzhen 518103, China
| | - Yujia Jiang
- BGI-Shenzhen, Shenzhen 518103, China; BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450000, China
| | - Jian Peng
- BGI-Shenzhen, Shenzhen 518103, China
| | - Shuai Liu
- BGI-Shenzhen, Shenzhen 518103, China
| | | | - Chuanyu Liu
- BGI-Shenzhen, Shenzhen 518103, China; Shenzhen Bay Laboratory, Shenzhen 518000, China
| | | | - Yue Yuan
- BGI-Shenzhen, Shenzhen 518103, China
| | | | - Huiwen Zheng
- BGI-Shenzhen, Shenzhen 518103, China; BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450000, China
| | - Weimin Feng
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Zhifeng Wang
- BGI-Shenzhen, Shenzhen 518103, China; Shenzhen Key Laboratory of Single-Cell Omics, BGI-Shenzhen, Shenzhen 518120, China
| | - Yang Liu
- BGI-Shenzhen, Shenzhen 518103, China
| | | | - Yunzhi Yang
- BGI-Shenzhen, Shenzhen 518103, China; BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450000, China
| | - Haitao Xiang
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Lei Han
- BGI-Shenzhen, Shenzhen 518103, China
| | - Baoming Qin
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Pengcheng Guo
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Guangyao Lai
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Pura Muñoz-Cánoves
- Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), ICREA and CIBERNED, Barcelona 08003, Spain; Spanish National Center on Cardiovascular Research (CNIC), Madrid 28029, Spain
| | - Patrick H Maxwell
- Cambridge Institute for Medical Research, Department of Medicine, University of Cambridge, Cambridge CB2 0XY, UK
| | | | - Qing-Feng Wu
- State Key Laboratory of Molecular Development Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China
| | | | | | - Mei Li
- BGI-Shenzhen, Shenzhen 518103, China
| | - Xi Dai
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Shuai Wang
- BGI-Shenzhen, Shenzhen 518103, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | | | | | - Liqun Wang
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
| | - Ji-Feng Fei
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
| | - Ou Wang
- BGI-Shenzhen, Shenzhen 518103, China
| | - Xiaofeng Wei
- China National GeneBank, BGI-Shenzhen, Shenzhen 518120, China
| | - Haorong Lu
- China National GeneBank, BGI-Shenzhen, Shenzhen 518120, China
| | - Bo Wang
- China National GeneBank, BGI-Shenzhen, Shenzhen 518120, China
| | - Shiping Liu
- BGI-Shenzhen, Shenzhen 518103, China; Shenzhen Key Laboratory of Single-Cell Omics, BGI-Shenzhen, Shenzhen 518120, China
| | - Ying Gu
- BGI-Shenzhen, Shenzhen 518103, China; Guangdong Provincial Key Laboratory of Genome Read and Write, Shenzhen 518120, China
| | - Ming Ni
- MGI, BGI-Shenzhen, Shenzhen 518083, China
| | - Wenwei Zhang
- BGI-Shenzhen, Shenzhen 518103, China; Shenzhen Key Laboratory of Neurogenomics, BGI-Shenzhen, Shenzhen 518103, China
| | - Feng Mu
- MGI, BGI-Shenzhen, Shenzhen 518083, China
| | - Ye Yin
- BGI-Shenzhen, Shenzhen 518103, China; BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China
| | - Huanming Yang
- BGI-Shenzhen, Shenzhen 518103, China; James D. Watson Institute of Genome Sciences, Hangzhou 310058, China
| | - Michael Lisby
- Department of Biology, University of Copenhagen, Copenhagen 2200, Denmark
| | - Richard J Cornall
- Medical Research Council Human Immunology Unit, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK
| | - Jan Mulder
- Department of Protein Science, Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm 17121, Sweden; Department of Neuroscience, Karolinska Institute, Stockholm 17177, Sweden
| | - Mathias Uhlén
- Department of Protein Science, Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm 17121, Sweden; Department of Neuroscience, Karolinska Institute, Stockholm 17177, Sweden
| | - Miguel A Esteban
- BGI-Shenzhen, Shenzhen 518103, China; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; Institute of Stem Cells and Regeneration, Chinese Academy of Sciences, Beijing 100101, China.
| | | | - Longqi Liu
- BGI-Shenzhen, Shenzhen 518103, China; BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450000, China; Shenzhen Bay Laboratory, Shenzhen 518000, China.
| | - Xun Xu
- BGI-Shenzhen, Shenzhen 518103, China; Guangdong Provincial Key Laboratory of Genome Read and Write, Shenzhen 518120, China.
| | - Jian Wang
- BGI-Shenzhen, Shenzhen 518103, China; James D. Watson Institute of Genome Sciences, Hangzhou 310058, China.
| |
Collapse
|
7
|
Yang M, Huang L, Huang H, Tang H, Zhang N, Yang H, Wu J, Mu F. Integrating convolution and self-attention improves language model of human genome for interpreting non-coding regions at base-resolution. Nucleic Acids Res 2022; 50:e81. [PMID: 35536244 PMCID: PMC9371931 DOI: 10.1093/nar/gkac326] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 02/22/2022] [Accepted: 05/09/2022] [Indexed: 12/12/2022] Open
Abstract
Interpretation of non-coding genome remains an unsolved challenge in human genetics due to impracticality of exhaustively annotating biochemically active elements in all conditions. Deep learning based computational approaches emerge recently to help interpret non-coding regions. Here, we present LOGO (Language of Genome), a self-attention based contextualized pre-trained language model containing only two self-attention layers with 1 million parameters as a substantially light architecture that applies self-supervision techniques to learn bidirectional representations of the unlabelled human reference genome. LOGO is then fine-tuned for sequence labelling task, and further extended to variant prioritization task via a special input encoding scheme of alternative alleles followed by adding a convolutional module. Experiments show that LOGO achieves 15% absolute improvement for promoter identification and up to 4.5% absolute improvement for enhancer-promoter interaction prediction. LOGO exhibits state-of-the-art multi-task predictive power on thousands of chromatin features with only 3% parameterization benchmarking against the fully supervised model, DeepSEA and 1% parameterization against a recent BERT-based DNA language model. For allelic-effect prediction, locality introduced by one dimensional convolution shows improved sensitivity and specificity for prioritizing non-coding variants associated with human diseases. In addition, we apply LOGO to interpret type 2 diabetes (T2D) GWAS signals and infer underlying regulatory mechanisms. We make a conceptual analogy between natural language and human genome and demonstrate LOGO is an accurate, fast, scalable, and robust framework to interpret non-coding regions for global sequence labeling as well as for variant prioritization at base-resolution.
Collapse
Affiliation(s)
- Meng Yang
- MGI, BGI-Shenzhen, Shenzhen 518083, China.,Department of Biology, University of Copenhagen, Copenhagen DK-2200, Denmark
| | | | | | - Hui Tang
- MGI, BGI-Shenzhen, Shenzhen 518083, China
| | - Nan Zhang
- MGI, BGI-Shenzhen, Shenzhen 518083, China
| | - Huanming Yang
- BGI-Shenzhen, Shenzhen 518083, China.,Guangdong Provincial Academician Workstation of BGI Synthetic Genomics, BGI-Shenzhen, Shenzhen, 518120, China
| | - Jihong Wu
- Department of Ophthalmology, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.,Shanghai Key Laboratory of Visual Impairment and Restoration, Science and Technology Commission of Shanghai Municipality, Shanghai, China.,Key Laboratory of Myopia (Fudan University), Chinese Academy of Medical Sciences, National Health Commission, Shanghai, China
| | - Feng Mu
- MGI, BGI-Shenzhen, Shenzhen 518083, China
| |
Collapse
|
8
|
Maselli D, Carstens D, Yang D, Mu F, Young J, Cook E, Betts K, Chung Y. P061 BENRALIZUMAB IS EFFECTIVE IN REDUCING ASTHMA EXACERBATIONS: RESULTS FROM THE ZEPHYR 2 STUDY. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Chen JB, Kong XF, Mu F, Lu TY, Lu YY, Xu KC. Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer. Med Gas Res 2021; 10:75-80. [PMID: 32541132 PMCID: PMC7885710 DOI: 10.4103/2045-9912.285560] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Chemotherapy, targeted therapy, and immunotherapy are used against advanced non-small cell lung cancer. A clinically efficacious method for relieving the adverse events associated of such therapies is lacking. Fifty-eight adult patients were enrolled in our trial to relieve pulmonary symptoms or the adverse events of drugs. Twenty patients who refused drug treatment were assigned equally and randomly to a hydrogen (H2)-only group and a control group. According to the results of tumor-gene mutations and drug-sensitivity tests, 10, 18, and 10 patients were enrolled into chemotherapy, targeted therapy, and immunotherapy groups in which these therapies were combined with H2-therapy, respectively. Patients underwent H2 inhalation for 4–5 hours per day for 5 months or stopped when cancer recurrence. Before study initiation, the demographics (except for tumor-mutation genes) and pulmonary symptoms (except for moderate cough) of the five groups showed no significant difference. During the first 5 months of treatment, the prevalence of symptoms of the control group increased gradually, whereas that of the four treatment groups decreased gradually. After 16 months of follow-up, progression-free survival of the control group was lower than that of the H2-only group, and significantly lower than that of H2 + chemotherapy, H2 + targeted therapy, and H2 + immunotherapy groups. In the combined-therapy groups, most drug-associated adverse events decreased gradually or even disappeared. H2 inhalation was first discovered in the clinic that can be used to control tumor progression and alleviate the adverse events of medications for patients with advanced non-small cell lung cancer. This study was approved by the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval No. Fuda20181207), and was registered at ClinicalTrials.gov (Identifier: NCT03818347) on January 28, 2019.
Collapse
Affiliation(s)
- Ji-Bing Chen
- Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China
| | - Xiao-Feng Kong
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Feng Mu
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Tian-Yu Lu
- Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China
| | - You-Yong Lu
- Central Lab, Beijing Cancer Hospital, Beijing, China
| | - Ke-Cheng Xu
- Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China
| |
Collapse
|
10
|
Liang T, Wu F, Wang B, Mu F. PRISMA: accuracy of response entropy and bispectral index to predict the transition of consciousness during sevoflurane anesthesia: A systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e25718. [PMID: 33907161 PMCID: PMC8084050 DOI: 10.1097/md.0000000000025718] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 03/15/2021] [Accepted: 04/12/2021] [Indexed: 11/27/2022] Open
Abstract
Background: Bispectral index (BIS) and response entropy (RE) are used to monitor the depth of anesthesia. Objectives: To collect published data and compare the accuracy of BIS and RE in detecting the transition of consciousness during sevoflurane anesthesia. Data sources: Studies indexed in the PubMed, Embase, or Cochrane databases. Study eligibility criteria: Participants: Patients who need to use BIS and RE to monitor sevoflurane anesthesia depth simultaneously. Interventions: A random-effects model was fitted using RevMan 5.3. Subgroup analyses were performed on patient age. The Cochrane I 2 methodology was used to determine the heterogeneity of the statistical results, while GRADE Pro served to assess the quality of evidence. Results: Overall, 195 articles were identified, of which 7 were finally included. The meta-analysis results showed that BIS is more accurate than RE in predicting loss of consciousness (LOC) during sevoflurane anesthesia (MD, .06; 95% confidence interval [CI], .02–.09; P = .009; I 2 = 92%). In contrast, there was no significant difference between BIS and RE for recovery of consciousness (ROC; MD, .01; 95% CI, .00–.02; P = .79; I 2 = 83%). Subgroup analyses revealed no significant differences in LOC (MD, .02; 95% CI, .01–.05; P = .13; I 2 = 60%) and ROC (MD, −.01; 95% CI, −.06–.04; P = .58; I 2 = 95%) in children. However, the results in adults demonstrated that BIS is more accurate than RE in predicting LOC (MD, −.07; 95% CI, .05–.10; P = .002; I 2 = 76%). Limitations: First, this meta-analysis was affected by a large study heterogeneity. Second, this analysis only included publications in English, therefore, some studies may have been omitted. Conclusion: BIS is more accurate than RE in predicting LOC during sevoflurane anesthesia in adults. However, no significant differences were identified in children. Registration number (PROSPERO): CRD42020163119
Collapse
Affiliation(s)
- Tao Liang
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing
| | - Fan Wu
- Department of Anesthesiology, Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China
| | - Baoguo Wang
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing
| | - Feng Mu
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing
| |
Collapse
|
11
|
Qu S, Zhang Y, Yang X, Tan Y, Li M, Yang X, Zhou L, Chen D, Chen Y, Yan M, Wang Q, Yu T, Sun N, Jiang H, Su F, Di Y, Lin G, Yuan Y, Chen F, Mu F, Huang J. The Setup and Application of Reference Material in Sequencing-Based Noninvasive Prenatal Testing. Gynecol Obstet Invest 2021; 86:123-131. [PMID: 33784691 DOI: 10.1159/000513472] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 11/30/2020] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The sequencing-based noninvasive prenatal testing (NIPT) has been successfully integrated into clinical practice and facilitated the early detection of fetal chromosomal anomalies. However, a comprehensive reference material to evaluate and quality control NIPT services from different NIPT providers remains unavailable. METHODS In this study, we established a set of NIPT reference material consisting of 192 simulated samples. Most of the potential factors influencing the accuracy of NIPT, such as fetal fraction, mosaicism, and interfering substances, were included in the reference material. We compared the performance of chromosomal abnormalities detection on 3 widely used sequencers (NextSeq 500, BGISEQ-500, and Ion Proton) based on the reference material. RESULTS All 3 sequencers provided highly accurate and reliable results to samples with ≥3.5% fetal fractions and high percentage of mosaicism. CONCLUSIONS The established reference material can serve as a universal standard quality control for the current and new-coming NIPT providers based on various sequencers.
Collapse
Affiliation(s)
- Shoufang Qu
- National Institutes for Food and Drug Control (NIFDC), Beijing, China
| | | | - Xin Yang
- Yantai Yuhuangding Hospital, Yantai, China
| | - Yueqiu Tan
- Institute of Reproductive and Stem Cell Engineering, Central South University, Changsha, China.,Key Laboratory of Stem Cell and Reproductive Engineering, Ministry of Health, Changsha, China
| | - Ming Li
- Guangzhou Darui Biotechnology Co., Ltd., Guangzhou, China
| | - Xuexi Yang
- R&D, Southern Medical University, Guangzhou, China
| | - Lijun Zhou
- BGI-Genomics, BGI-Shenzhen, Shenzhen, China
| | - Di Chen
- Berry Genomics Corporation, Beijing, China
| | | | | | | | - Ting Yu
- National Institutes for Food and Drug Control (NIFDC), Beijing, China
| | - Nan Sun
- National Institutes for Food and Drug Control (NIFDC), Beijing, China
| | | | | | - Yufen Di
- Institute of Reproductive and Stem Cell Engineering, Central South University, Changsha, China.,Key Laboratory of Stem Cell and Reproductive Engineering, Ministry of Health, Changsha, China
| | - Ge Lin
- Key Laboratory of Stem Cell and Reproductive Engineering, Ministry of Health, Changsha, China
| | | | | | - Feng Mu
- BGI-Shenzhen, Shenzhen, China
| | - Jie Huang
- National Institutes for Food and Drug Control (NIFDC), Beijing, China
| |
Collapse
|
12
|
Abstract
Hydrogen inhalation therapy has been proven to be safe and effective in disease treatment in multiple clinical reports, but the gas flow rates used in different studies vary greatly. Since there is no upper limit for the safe concentration of hydrogen, this study tested the effects of high-flow (not high concentration) hydrogen inhalation on immune function. From October 2019 to January 2020, 20 adult participants (31-60 years old) were enrolled in a self-controlled study to check the immune function in peripheral blood lymphocyte subsets before and after a 2-week hydrogen inhalation protocol. The participants inhaled hydrogen for 2 or 4 hours each day. After 2 weeks of hydrogen inhalation, statistically significant changes were observed in follicular helper T cells, helper and cytotoxic T cells, natural killer and natural killer T cells, and gamma delta T cells, generally suggesting a decrease in their proportions. These results show that high-flow hydrogen inhalation has an inhibitory effect on the immune function of healthy participants. The study protocol received ethical approval from the Ethics Committee of Fuda Cancer Hospital, Jinan University on December 7, 2018 (approval No. Fuda20181207).
Collapse
Affiliation(s)
- Ji-Bing Chen
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Xiao-Feng Kong
- Xu Kecheng Care Health Studio of Guangdong Province, Guangzhou, Guangdong Province, China
| | - Feng Mu
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| |
Collapse
|
13
|
Chen JB, Kong XF, Qian W, Mu F, Lu TY, Lu YY, Xu KC. Two weeks of hydrogen inhalation can significantly reverse adaptive and innate immune system senescence patients with advanced non-small cell lung cancer: a self-controlled study. Med Gas Res 2021; 10:149-154. [PMID: 33380580 PMCID: PMC8092147 DOI: 10.4103/2045-9912.304221] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Following standard treatments, the traditional model for enhancing anti-tumor immunity involves performing immune reconstitution (e.g., adoptive immune cell therapies or immunoenhancing drugs) to prevent recurrence. For patients with advanced non-small cell lung cancer, we report here on two objectives, the immunosenescence for advanced non-small cell lung cancer and hydrogen gas inhalation for immune reconstitution. From July 1st to September 25th, 2019, 20 non-small cell lung cancer patients were enrolled to evaluate the immunosenescence of peripheral blood lymphocyte subsets, including T cell, natural killer/natural killer T cell and gamma delta T cell. Two weeks of hydrogen inhalation was performed during the waiting period for treatment-related examination. All patients inhaled a mixture of hydrogen (66.7%) and oxygen (33.3%) with a gas flow rate of 3 L/min for 4 hours each day. None of the patients received any standard treatment during the hydrogen inhalation period. After pretreatment testing, major indexes of immunosenescence were observed. The abnormally higher indexes included exhausted cytotoxic T cells, senescent cytotoxic T cells, and killer Vδ1 cells. After 2 weeks of hydrogen therapy, the number of exhausted and senescent cytotoxic T cells decreased to within the normal range, and there was an increase in killer Vδ1 cells. The abnormally lower indexes included functional helper and cytotoxic T cells, Th1, total natural killer T cells, natural killer, and Vδ2 cells. After 2 weeks of hydrogen therapy, all six cell subsets increased to within the normal range. The current data indicate that the immunosenescence of advanced non-small cell lung cancer involves nearly all lymphocyte subsets, and 2 weeks of hydrogen treatment can significantly improve most of these indexes. The study was approved by the Ethics Committee of Fuda Cancer Hospital, Jinan University in China (approval No. Fuda20181207) on December 7th, 2018, and was registered on ClinicalTrials.gov (ID: NCT03818347) on January 24th, 2019.
Collapse
Affiliation(s)
- Ji-Bing Chen
- Fuda Cancer Hospital of Jinan University; Fuda Cancer Institute, Guangzhou, Guangdong Province, China
| | - Xiao-Feng Kong
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Wei Qian
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Feng Mu
- Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Tian-Yu Lu
- Fuda Cancer Hospital of Jinan University; Fuda Cancer Institute, Guangzhou, Guangdong Province, China
| | - You-Yong Lu
- Central Laboratory, Peking University Cancer Hospital, Beijing, China
| | - Ke-Cheng Xu
- Fuda Cancer Hospital of Jinan University; Fuda Cancer Institute, Guangzhou, Guangdong Province, China
| |
Collapse
|
14
|
Rao J, Peng L, Liang X, Jiang H, Geng C, Zhao X, Liu X, Fan G, Chen F, Mu F. Performance of copy number variants detection based on whole-genome sequencing by DNBSEQ platforms. BMC Bioinformatics 2020; 21:518. [PMID: 33176676 PMCID: PMC7659224 DOI: 10.1186/s12859-020-03859-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 11/03/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND DNBSEQ™ platforms are new massively parallel sequencing (MPS) platforms that use DNA nanoball technology. Use of data generated from DNBSEQ™ platforms to detect single nucleotide variants (SNVs) and small insertions and deletions (indels) has proven to be quite effective, while the feasibility of copy number variants (CNVs) detection is unclear. RESULTS Here, we first benchmarked different CNV detection tools based on Illumina whole-genome sequencing (WGS) data of NA12878 and then assessed these tools in CNV detection based on DNBSEQ™ sequencing data from the same sample. When the same tool was used, the CNVs detected based on DNBSEQ™ and Illumina data were similar in quantity, length and distribution, while great differences existed within results from different tools and even based on data from a single platform. We further estimated the CNV detection power based on available CNV benchmarks of NA12878 and found similar precision and sensitivity between the DNBSEQ™ and Illumina platforms. We also found higher precision of CNVs shorter than 1 kbp based on DNBSEQ™ platforms than those based on Illumina platforms by using Pindel, DELLY and LUMPY. We carefully compared these two available benchmarks and found a large proportion of specific CNVs between them. Thus, we constructed a more complete CNV benchmark of NA12878 containing 3512 CNV regions. CONCLUSIONS We assessed and benchmarked CNV detections based on WGS with DNBSEQ™ platforms and provide guidelines for future studies.
Collapse
Affiliation(s)
- Junhua Rao
- MGI, BGI-Shenzhen, Shenzhen, 518083, China
| | | | | | - Hui Jiang
- MGI, BGI-Shenzhen, Shenzhen, 518083, China
| | | | - Xia Zhao
- MGI, BGI-Shenzhen, Shenzhen, 518083, China
| | - Xin Liu
- BGI-Shenzhen, Shenzhen, 518083, China.,BGI-Qingdao, BGI-Shenzhen, Qingdao, 266555, Shandong, China.,IGDB-BGI Joint Center for Omics, BGI-Shenzhen, Shenzhen, 518083, China.,State Key Laboratory of Agricultural Genomics, BGI-Shenzhen, Shenzhen, 518083, China
| | - Guangyi Fan
- BGI-Qingdao, BGI-Shenzhen, Qingdao, 266555, Shandong, China.,State Key Laboratory of Agricultural Genomics, BGI-Shenzhen, Shenzhen, 518083, China
| | - Fang Chen
- MGI, BGI-Shenzhen, Shenzhen, 518083, China. .,BGI-Shenzhen, Shenzhen, 518083, China. .,China National GeneBank, BGI-Shenzhen, Shenzhen, 518120, China.
| | - Feng Mu
- MGI, BGI-Shenzhen, Shenzhen, 518083, China. .,MGI-Wuhan, BGI-Shenzhen, Wuhan, 430074, China.
| |
Collapse
|
15
|
Xiong J, Wang H, Mu F, Liu Z, Bao Y, Sun Y. MiR-125b-5p Inhibitor Might Protect Against Sevoflurane-induced Cognitive Impairments by Targeting LIMK1. Curr Neurovasc Res 2020; 16:382-391. [PMID: 31490755 DOI: 10.2174/1567202616666190906145936] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Revised: 07/25/2019] [Accepted: 08/07/2019] [Indexed: 01/05/2023]
Abstract
PURPOSE Research has shown that exposure to anesthesia might increase the risks of cognitive impairments and learning difficulties. MiR-125b-5p contributed to anesthesia-induced hippocampal apoptosis. However, the role of miR-125b-5p in sevoflurane-induced cognitive impairments remains unclear. METHODS Firstly, sevoflurane was used to establish a rat model and cognitive impairment was detected by the Morris water maze (MWM) test. The hippocampus was observed by HE staining. The lentivirus-miR-125b-5p antagomiR was transfected into rats to decrease miR-125b-5p. The interaction between miR-125b-5p and LIM domain kinase 1 (LIMK1) was confirmed by the luciferase reporter assay. The mRNA and expression levels of related genes and mRNA were examined by the Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) and western blot. RESULTS Sevoflurane induced the cognitive dysfunction presenting with longer latency time and few platform crossings in rats. Moreover, miR-125b-5p was observed to be up-regulated in both sevoflurane-anesthesia rats and sevoflurane-treated SH-SY5Y cells. More importantly, a decrease in miR-125b-5p could prevent sevoflurane-induced hippocampal apoptosis and inflammation in rats. Moreover, LIMK1 was the target gene of miR-125b-5p. Interestingly, si-LIMK1 could restore the sevoflurane-induced cell apoptosis in SH-SY5Y cells, which was alleviated by miR-125b-5p inhibitor. Finally, the miR-125b-5p inhibitor shortened the time to find the platform and increased the number of platform crossings compared to sevoflurane-anesthesia rats in the Morris water maze test. At the same time, the expression of LIMK1 was dramatically increased. CONCLUSION Altogether, these findings suggested that miR-125b-5p inhibitor could protect against the sevoflurane-induced cognitive impairments by targeting LIMK1.
Collapse
Affiliation(s)
- Jun Xiong
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing City, 100093, China
| | - Huijun Wang
- Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing City, 100730, China
| | - Feng Mu
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing City, 100093, China
| | - Zhanxue Liu
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing City, 100093, China
| | - Yin Bao
- Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing City, 100730, China
| | - Yongxing Sun
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing City, 100093, China
| |
Collapse
|
16
|
Xie Q, Wang J, You JL, Zhu SD, Zhou R, Tian ZJ, Wu H, Lin Y, Chen W, Xiao L, Li JJ, Dong J, Wu HL, Zhang W, Li J, Mu F, Xu X, Yin Y, Chen WJ, Wang J. [The role of large-scale testing platform in the prevention and control of the COVID-19 pandemic: an empirical study based on a novel numerical model]. Zhonghua Yi Xue Za Zhi 2020; 100:2532-2536. [PMID: 32829601 DOI: 10.3760/cma.j.cn112137-20200320-00860] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: China adopted an unprecedented province-scale quarantine since January 23rd 2020, after the novel coronavirus (COVID-19) broke out in Wuhan in December 2019. Responding to the challenge of limited testing capacity, large-scale (>20 000 tests per day) standardized and fully-automated laboratory (Huo-Yan) was built as an ad-hoc measure. There is so far no empirical data or mathematical model to reveal the impact of the testing capacity improvement since quarantine. Methods: Based on the suspected case data released by the Health Commission of Hubei Province and the daily testing data of Huo-Yan Laboratory, the impact of detection capabilities on the realization of "clearing" and "clearing the day" of supected cases was simulated by establishing a novel non-linear and competitive compartments differential model. Results: Without the establishment of Huo-Yan, the suspected cases would increase by 47% to 33 700, the corresponding cost of quarantine would be doubled, the turning point of the increment of suspected cases and the achievement of "daily settlement" (all newly discovered suspected cases are diagnosed according to the nucleic acid testing result) would be delayed for a whole week and 11 days. If the Huo-Yan Laboratory could ran at its full capacity, the number of suspected cases could start to decrease at least a week earlier, the peak of suspected cases would be reduced by at least 44%, and the quarantine cost could be reduced by more than 72%. Ideally, if a daily testing capacity of 10 500 tests was achieved immediately after the Hubei lockdown, "daily settlement" for all suspected cases could be achieved. Conclusions: Large-scale, standardized clinical testing platform, with nucleic acid testing, high-throughput sequencing, and immunoprotein assessment capabilities, need to be implemented simultaneously in order to maximize the effect of quarantine and minimize the duration and cost of the quarantine. Such infrastructure, for both common times and emergencies, is of great significance for the early prevention and control of infectious diseases.
Collapse
Affiliation(s)
- Q Xie
- BGI-Shenzhen, Shenzhen 518083, China
| | - J Wang
- BGI-Shenzhen, Shenzhen 518083, China
| | - J L You
- BGI-Shenzhen, Shenzhen 518083, China
| | - S D Zhu
- BGI-Wuhan, Wuhan 430075, China
| | - R Zhou
- BGI-Wuhan, Wuhan 430075, China
| | | | - H Wu
- BGI-Wuhan, Wuhan 430075, China
| | - Y Lin
- BGI-Wuhan, Wuhan 430075, China
| | - W Chen
- BGI-Wuhan, Wuhan 430075, China
| | - L Xiao
- BGI-Wuhan, Wuhan 430075, China
| | - J J Li
- BGI-Shenzhen, Shenzhen 518083, China
| | - J Dong
- BGI PathoGenesis Pharmaceutical Technology, Shenzhen 518083, China
| | - H L Wu
- BGI PathoGenesis Pharmaceutical Technology, Shenzhen 518083, China
| | - W Zhang
- MGI-Wuhan, Wuhan 430075, China
| | - J Li
- MGI-Shenzhen, Shenzhen 518083, China
| | - F Mu
- MGI-Shenzhen, Shenzhen 518083, China
| | - X Xu
- BGI-Shenzhen, Shenzhen 518083, China
| | - Y Yin
- BGI-Shenzhen, Shenzhen 518083, China
| | - W J Chen
- BGI PathoGenesis Pharmaceutical Technology, Shenzhen 518083, China
| | - J Wang
- BGI-Shenzhen, Shenzhen 518083, China
| |
Collapse
|
17
|
Chen JB, Kong XF, Lv YY, Qin SC, Sun XJ, Mu F, Lu TY, Xu KC. "Real world survey" of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients. Med Gas Res 2020; 9:115-121. [PMID: 31552873 PMCID: PMC6779007 DOI: 10.4103/2045-9912.266985] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Advanced cancer treatment is a huge challenge and new ideas and strategies are required. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation. We conducted a prospective follow-up study of 82 patients with stage III and IV cancer treated with hydrogen inhalation using the "real world evidence" method. After 3-46 months of follow-up, 12 patients died in stage IV. After 4 weeks of hydrogen inhalation, patients reported significant improvements in fatigue, insomnia, anorexia and pain. Furthermore, 41.5% of patients had improved physical status, with the best effect achieved in lung cancer patients and the poorest in patients with pancreatic and gynecologic cancers. Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13-45 days (median 23 days) after hydrogen inhalation in 36.2%. The greatest marker decrease was in achieved lung cancer and the lowest in pancreatic and hepatic malignancies. Of the 80 cases with tumors visible in imaging, the total disease control rate was 57.5%, with complete and partial remission appearing at 21-80 days (median 55 days) after hydrogen inhalation. The disease control rate was significantly higher in stage III patients than in stage IV patients (83.0% and 47.7%, respectively), with the lowest disease control rate in pancreatic cancer patients. No hematological toxicity was observed although minor adverse reactions that resolved spontaneously were seen in individual cases. In patients with advanced cancer, inhaled hydrogen can improve patients' quality-of-life and control cancer progression. Hydrogen inhalation is a simple, low-cost treatment with few adverse reactions that warrants further investigation as a strategy for clinical rehabilitation of patients with advanced cancer. The study protocol received ethical approval from the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval number: Fuda20181207).
Collapse
Affiliation(s)
- Ji-Bing Chen
- Department of Cancer Rehabilitation, Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Xiao-Feng Kong
- Research Center of Hydrogen Medicine, Xukecheng Health Care Studio of Guangdong Province, Guangzhou, Guangdong Province, China
| | - You-Yong Lv
- Molecular Biology Laboratory of Cancer Hospital, Peking University, Beijing, China
| | - Shu-Cun Qin
- Institute of Hydrogen Medicine, Shandong Medical University, Jinan, Shandong Province, China
| | - Xue-Jun Sun
- Institute of Diving Medicine, Navy Medical University, Shanghai, China
| | - Feng Mu
- Department of Cancer Rehabilitation, Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Tian-Yu Lu
- Department of Cancer Rehabilitation, Fuda Cancer Hospital of Jinan University; Research Center of Hydrogen Medicine, Xukecheng Health Care Studio of Guangdong Province, Guangzhou, Guangdong Province, China
| | - Ke-Cheng Xu
- Department of Cancer Rehabilitation, Fuda Cancer Hospital of Jinan University; Research Center of Hydrogen Medicine, Xukecheng Health Care Studio of Guangdong Province, Guangzhou, Guangdong Province, China
| |
Collapse
|
18
|
Chen J, Qian W, Mu F, Niu L, Du D, Xu K. The future of cryoablation: An abscopal effect. Cryobiology 2020; 97:1-4. [PMID: 32097610 DOI: 10.1016/j.cryobiol.2020.02.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 02/20/2020] [Accepted: 02/21/2020] [Indexed: 01/10/2023]
Abstract
Cryoablation has become a popular modality to treat a variety of malignant tumors in solid organs and soft tissues. In the future, the use of cryoablation should focus on its abscopal effect. The present review discusses the increased immune response triggered by cryoablation alone or by cryoablation combined with immunotherapies, which can improve the immune response and limit immunosuppression. First, cryoablative techniques should be improved to increase the area of necrosis and reduce the area of apoptosis. Second, cryoablation should be combined with immunotherapies, for example, cyclophosphamide, natural killer cells, granulocyte monocyte colony stimulating factor (GM-CSF), cytotoxic T lymphocyte-associated antigen (CTLA)-4, and programmed death receptor 1 (PD)-1 inhibitors. Cryoablation could also be combined with Hydrogen gas molecules, which were shown recently to stimulate peroxisome proliferator activated receptor gamma coactivator (PGC)-1α, thereby promoting mitochondrial function, which might rescue exhausted CD8+ T cells, leading to prolonged progression-free survival and overall survival of patients with advanced colorectal cancer.
Collapse
Affiliation(s)
- Jibing Chen
- Fuda Cancer Hospital, Jinan University, Guangzhou, China
| | - Wei Qian
- Fuda Cancer Hospital, Jinan University, Guangzhou, China
| | - Feng Mu
- Fuda Cancer Hospital, Jinan University, Guangzhou, China
| | - Lizhi Niu
- Fuda Cancer Hospital, Jinan University, Guangzhou, China
| | - Duanming Du
- Intervention Dept. of Shenzhen Second People's Hospital, Shenzhen, 518035, China.
| | - Kecheng Xu
- Fuda Cancer Hospital, Jinan University, Guangzhou, China.
| |
Collapse
|
19
|
Zhang Q, Sun Y, Wang B, Wang S, Mu F, Zhang Y. Comparative study of the Ambu® AuraOnce™ laryngeal mask and endotracheal intubation in anesthesia airway management during neurosurgery. J Int Med Res 2020; 48:300060520902606. [PMID: 32036718 PMCID: PMC7111043 DOI: 10.1177/0300060520902606] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Objective To investigate the feasibility and efficacy of the Ambu® AuraOnce™ laryngeal mask (LMA) compared with endotracheal intubation (ETI) during supratentorial tumor resection in the right lateral decubitus position. Methods This was a randomized controlled trial of LMA compared with ETI in patients who were scheduled to undergo supratentorial tumor resection in the right lateral decubitus position. The patients were randomized to the LMA (n = 40) and ETI groups (n = 40). The hemodynamic parameters (primary outcome) and mechanical ventilation parameters, anesthetic dose, and complications as well as quality of anesthesia recovery (secondary outcomes) were compared. Results Patients in the LMA group exhibited lower mean arterial pressure (MAP) and heart rate (HR) compared with ETI. Nine and two patients received esmolol during intubation and extubation, respectively. The airway pressure (AP) in the LMA group was higher compared with the ETI group 60 minutes after the start of surgery. Compared with the ETI group, the sufentanil dose was lower by 24% and the anesthesia recovery rate was better in the LMA group. Conclusions LMA can improve hemodynamic stability in patients undergoing supratentorial tumor resection in the right lateral decubitus position. If there is a clinical need and no contraindication, LMA could replace ETI.
Collapse
Affiliation(s)
- Qiaoyun Zhang
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing, China
| | - Yongxing Sun
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing, China
| | - Baoguo Wang
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing, China
| | - Shuangyan Wang
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing, China
| | - Feng Mu
- Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing, China
| | - Yunxin Zhang
- Intensive Care Unit, Sanbo Brain Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
20
|
Mu F, Chen J, Liang B, Niu L, Zhou L, Zhang Z, Xu K. Cryosurgery And Radioactive Iodine Seeds Implantation For The Treatment Of Aggressive Thymoma. Cryobiology 2020. [DOI: 10.1016/j.cryobiol.2019.11.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Yang Y, Zhang Y, Wu Y, Chen J, Liang B, Chen Q, Wang Q, Lyu J, Li Y, Mu F, Du D. Efficacy and Safety of Percutaneous Argon-Helium Cryoablation for Hepatocellular Carcinoma Abutting the Diaphragm. J Vasc Interv Radiol 2020; 31:393-400.e1. [PMID: 31987705 DOI: 10.1016/j.jvir.2019.11.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 10/15/2019] [Accepted: 11/02/2019] [Indexed: 01/10/2023] Open
Abstract
PURPOSE To evaluate the efficacy and safety of percutaneous argon-helium cryoablation (CA) for hepatocellular carcinoma (HCC) abutting the diaphragm (<5 mm). MATERIALS AND METHODS A total of 61 consecutive patients (50 men, 11 women; mean age, 56.3 ± 12.1 years old; range, 32-83 years) with 74 HCC tumors (mean size, 3.3 ± 1.7 cm; range, 0.8-7 cm) who were treated with percutaneous argon-helium CA were enrolled in this retrospective study. Adverse events were evaluated according to Common Terminology Criteria for Adverse Events, version 5.0. Local tumor progression (LTP) and overall survival (OS) were analyzed using the Kaplan-Meier method and the log-rank test. The risk factors associated with OS and LTP were evaluated using univariate and multivariate Cox regression analysis. RESULTS No periprocedural (30-day) deaths occurred. A total of 29 intrathoracic adverse events occurred in 24 of the 61 patients. Major adverse events were reported in 5 patients (pleural effusion requiring catheter drainage in 4 patients and pneumothorax requiring catheter placement in 1 patient). Median follow-up was 18.7 months (range, 2.3-60.0 months). Median time to LTP after CA was 20.9 months (interquartile range [IQR], 14.1-30.6 months). Median times of OS after CA and diagnosis were 27.3 months (IQR, 15.1-45.1 months) and 40.9 months (interquartile range, 24.8-68.6 months), respectively. Independent prognostic factors for OS included tumor location (left lobe vs right lobe; hazard ratio [HR], 2.031; 95% confidence interval [CI], 1.062-3.885; P = .032) and number of intrahepatic tumors (solitary vs multifocal; HR, 2.684; 95% CI, 1.322-5.447; P = .006). Independent prognostic factors for LTP included age (HR, 0.931; 95% CI, 0.900-0.963; P < .001), guidance modality (ultrasound vs computed tomography and US; HR, 6.156 95% CI, 1.862-20.348; P = .003) and origin of liver disease. CONCLUSIONS Percutaneous argon-helium CA is safe for the treatment of HCC abutting the diaphragm, with acceptable LTP and OS.
Collapse
Affiliation(s)
- Yumei Yang
- Department of Ultrasound, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China
| | - Yanfang Zhang
- Department of Interventional Therapy, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, China
| | - Yumin Wu
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, China
| | - Jibing Chen
- Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, China
| | - Bing Liang
- Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
| | - Quanhong Chen
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, China
| | - Qiuyu Wang
- Department of Radiology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China
| | - Jialing Lyu
- Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, China
| | - Yong Li
- Department of Interventional Therapy, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, China
| | - Feng Mu
- Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
| | - Duanming Du
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, China.
| |
Collapse
|
22
|
Chen J, Mu F, Lu T, Du D, Xu K. Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report. Onco Targets Ther 2019; 12:11145-11151. [PMID: 31908482 PMCID: PMC6927257 DOI: 10.2147/ott.s235195] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 11/28/2019] [Indexed: 01/10/2023] Open
Abstract
Lung cancer is the most common type of tumor, prone to contralateral lung, bone and brain metastasis. We report a 44-year-old woman diagnosed with lung cancer with multiple metastases in November 2015. Oral targeted drugs were initiated after the removal of brain metastases, and most lesions remained stable for 28 months. In March 2018, intracranial multiple metastases, as well as hydrocephalus accumulation in the third ventricle and lateral ventricles, and metastases in bone, adrenal gland, liver were noted. Hydrogen-gas monotherapy was started to control the tumor a month later. After 4 months, the size of multiple brain tumors was reduced significantly, and the amount of hydrocephalus in the third ventricle and lateral ventricles reduced significantly. After 1 year, all brain tumors had disappeared, and there were no significant changes in metastases in the liver and lung. These data show that, after standard treatments had failed, hydrogen-gas monotherapy elicited significant effective control of tumors (especially those in the brain), and survival time was lengthened.
Collapse
Affiliation(s)
- Jibing Chen
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| | - Feng Mu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| | - Tianyu Lu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| | - Duanming Du
- Intervention Department of Shenzhen Second People's Hospital, Shenzhen 518035, People's Republic of China
| | - Kecheng Xu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| |
Collapse
|
23
|
Chen J, Kong X, Mu F, Lu T, Du D, Xu K. Hydrogen–oxygen therapy can alleviate radiotherapy-induced hearing loss in patients with nasopharyngeal cancer. Ann Palliat Med 2019; 8:746-751. [PMID: 31865734 DOI: 10.21037/apm.2019.11.18] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 11/05/2019] [Indexed: 01/10/2023]
Affiliation(s)
- Jibing Chen
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China
| | - Xiaofeng Kong
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China
| | - Feng Mu
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China
| | - Tianyu Lu
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China
| | - Duanming Du
- Intervention Department, Shenzhen Second People's Hospital, Shenzhen 518035, China
| | - Kecheng Xu
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China.
| |
Collapse
|
24
|
Chen J, Mu F, Lu T, Ma Y, Du D, Xu K. A Gallbladder Carcinoma Patient With Pseudo-Progressive Remission After Hydrogen Inhalation. Onco Targets Ther 2019; 12:8645-8651. [PMID: 31695424 PMCID: PMC6804672 DOI: 10.2147/ott.s227217] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Accepted: 10/03/2019] [Indexed: 01/10/2023] Open
Abstract
Background Hydrogen therapy has been reported to convert exhausted programmed cell death receptor (PD-1)+CD8+ T cells to PD-1-CD8+ T cells, in advanced colorectal cancer patients, which is associated with significantly prolonged survival. Case presentation A 72-year-old female patient presented with metastatic gallbladder cancer and underwent symptomatic treatment combined with hydrogen therapy. The tumors were initially enlarged and displayed increased tumor marker expression following hydrogen inhalation therapy, after which they continued to remit, similar to the pseudo-progression that occurs after anti-PD-1 treatment. During one month of hydrogen therapy, the patient's gallbladder and liver tumors continued to progress, and intestinal obstruction occurred. The intestinal obstruction was gradually relieved after symptomatic treatment, and the metastases in the abdominal cavity gradually decreased in size, anemia and hypoalbuminemia were corrected, and both the lymphocyte and tumor marker levels returned to normal. The patient was able to resume normal life two and a half months after hydrogen inhalation and survived over 10 months. Conclusion This is the first report of pseudo-progression followed by sustained remission after hydrogen inhalation. This phenomenon is similar to the pseudo-progression-remission pattern that occurs following PD-1 antibody treatment. These findings suggest that hydrogen may have an inhibitory effect on PD-1 expression.
Collapse
Affiliation(s)
- Jibing Chen
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China.,Fuda Cancer Institute of Guangzhou City, Guangzhou 510665, People's Republic of China
| | - Feng Mu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| | - Tianyu Lu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| | - Yangyang Ma
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China
| | - Duanming Du
- Intervention Department, The Second People's Hospital of Shenzhen, Shenzhen 518035, People's Republic of China
| | - Kecheng Xu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, People's Republic of China.,Fuda Cancer Institute of Guangzhou City, Guangzhou 510665, People's Republic of China
| |
Collapse
|
25
|
Chen JB, Pan ZB, Du DM, Qian W, Ma YY, Mu F, Xu KC. Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report. World J Clin Cases 2019; 7:2065-2074. [PMID: 31423439 PMCID: PMC6695532 DOI: 10.12998/wjcc.v7.i15.2065] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2019] [Revised: 06/17/2019] [Accepted: 06/27/2019] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND We present the case of a 72-year-old female patient with gallbladder cancer (GBC) who developed in situ recurrence and liver metastases 9 mo after irreversible electroporation ablation and oral tegafur (a fluoropyrimidine derivative) chemotherapy, which failed to control the progression of the disease. The patient further developed metastases in the lymph nodes around the head of the pancreas. The patient had severe anemia, requiring weekly blood transfusions. The gallbladder tumor invaded the descending part of the duodenum, causing intestinal leakage and hepatic colonic adhesion.
CASE SUMMARY The patient refused other treatments and began daily hydrogen inhalation therapy. After 1 mo of treatment, the gallbladder and liver tumors continued to progress, and intestinal obstruction occurred. After continuous hydrogen therapy and symptomatic treatments including gastrointestinal decompression and intravenous nutrition support, the intestinal obstruction was gradually relieved. Three months after hydrogen therapy, the metastases in the abdominal cavity gradually reduced in size, her anemia and hypoalbuminemia were corrected, lymphocyte and tumor marker levels returned to normal, and the patient was able to resume normal life.
CONCLUSION This is the first report of an efficacy and safety study about hydrogen therapy in patient with metastatic GBC and a critical general condition, who has remained stable for more than 4 months.
Collapse
Affiliation(s)
- Ji-Bing Chen
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, Guangdong Province, China
| | - Zhong-Bao Pan
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, Guangdong Province, China
| | - Duan-Ming Du
- Intervention Department of Shenzhen Second People’s Hospital, Shenzhen 518035, Guangdong Province, China
| | - Wei Qian
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, Guangdong Province, China
| | - Yang-Yang Ma
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, Guangdong Province, China
| | - Feng Mu
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, Guangdong Province, China
| | - Ke-Cheng Xu
- Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, Guangdong Province, China
| |
Collapse
|
26
|
Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. 化脓性汗腺炎对工作损失、间接成本和收入的影响. Br J Dermatol 2019. [DOI: 10.1111/bjd.18069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of HS on work loss, indirect costs and income. Br J Dermatol 2019. [DOI: 10.1111/bjd.18053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Sun Y, Meng R, Tang H, Wang H, Guo X, Ma Y, Yang Y, Wei X, Mu F, Wu G, Wang J, Liu J, Niu M, Xue J. Design of a liver cancer-specific selector for the analysis of circulating tumor DNA. Oncol Lett 2019; 17:5369-5376. [PMID: 31186754 PMCID: PMC6507330 DOI: 10.3892/ol.2019.10243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2016] [Accepted: 02/25/2019] [Indexed: 01/17/2023] Open
Abstract
Circulating tumor DNA (ctDNA) has been frequently investigated to monitor tumor dynamics and measure tumor burden. This non-invasive method concerning ctDNA has been recognized as a promising biomarker. Recently, next generation sequencing has been used in ctDNA detection by researchers. However, those reports have been limited by modest sensitivity, and only a minority of patients with cancer were applicable. Additionally, a limited number of cases of liver cancer have been analyzed. A more precise method is required to be established to evaluate ctDNA noninvasively. In the present study, a novel method to design a liver cancer-associated chip region (spanning 211 kb, containing 159 genes) was performed with high specificity using International Cancer Genome Consortium datasets. Following evaluation with datasets from The Cancer Genome Atlas and data from 3 patients with liver cancer, the selected regions were demonstrated to be beneficial to locate specific somatic mutations associated with liver cancer therapy and to monitor cancer dynamics in the plasma samples of the patients. In addition to establishing performance benchmarks supporting direct clinical use, the chip designed and the high-resolution sequencing analyses pipeline would allow the development a set of patient specific markers that could monitor the process of cancer with high accuracy and low cost. Furthermore, the present study is essential to understanding the dynamics and providing insight into the basic mechanisms of liver cancer.
Collapse
Affiliation(s)
- Yan Sun
- Department of Biology, University of Copenhagen, Copenhagen DK-2200, Denmark.,BGI Genomics, BGI-Shenzhen, Shenzhen, Guangdong 518083, P.R. China.,Wuhan Medical Laboratory, BGI-Wuhan, Wuhan, Hubei 430075, P.R. China
| | - Rui Meng
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
| | - Heng Tang
- Hefei Anweikang Medical Laboratory, Hefei, Anhui 230000, P.R. China
| | - Huimin Wang
- Department of Neurology, Xinxiang Central Hospital, Xinxiang, Henan 453000, P.R. China
| | - Xueqin Guo
- Wuhan Medical Laboratory, BGI-Wuhan, Wuhan, Hubei 430075, P.R. China
| | - Yuanyuan Ma
- BGI Genomics, BGI-Shenzhen, Shenzhen, Guangdong 518083, P.R. China
| | - Yun Yang
- Wuhan Medical Laboratory, BGI-Wuhan, Wuhan, Hubei 430075, P.R. China
| | - Xiaoming Wei
- Wuhan Medical Laboratory, BGI-Wuhan, Wuhan, Hubei 430075, P.R. China
| | - Feng Mu
- Wuhan Medical Laboratory, BGI-Wuhan, Wuhan, Hubei 430075, P.R. China
| | - Gang Wu
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
| | - Jun Wang
- Department of Biology, University of Copenhagen, Copenhagen DK-2200, Denmark.,BGI Genomics, BGI-Shenzhen, Shenzhen, Guangdong 518083, P.R. China
| | - Jun Liu
- Department of Bioscience and Bioengineering, South China University, Guangzhou, Guangdong 510641, P.R. China.,Tianjin Medical Laboratory, BGI-Tianjin, Tianjin 300308, P.R. China
| | - Mingshan Niu
- Jiangsu Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China
| | - Jun Xue
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
| |
Collapse
|
29
|
Chen J, Lv Y, Mu F, Xu K. Long-term response of metastatic renal clear cell carcinoma following a subcutaneous injection of mixed bacterial vaccine: a case report. Onco Targets Ther 2019; 12:2531-2538. [PMID: 31040696 PMCID: PMC6454994 DOI: 10.2147/ott.s200414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
In this study, we present the case of a 56-year-old patient with renal clear cell carcinoma who developed lung metastases 13 months after nephrectomy and subsequently received tyrosine kinase inhibitor (sunitinib) and PD-1 antibody (nivolumab) immunotherapy, which failed to control the progression of the disease. The patient further developed metastases to the left pleura, bilateral hilar lymph nodes, liver, right lower kidney, scapula, left sixth rib, right tonsil, and other organs. There was severe anemia, requiring weekly blood transfusions. Karnofsky score was 30. After receiving mixed bacterial vaccine (MBV) consisting of 6 kinds of heat-inactivated bacteria plus Poly I:C, the patient’s condition rapidly improved, systemic metastases gradually reduced in size or disappeared, anemia was corrected, and the patient was able to resume normal life and work. MBV treatment in the setting of failure of previous immunotherapy treatment appears to have achieved objective response for this patient with metastatic renal clear cell carcinoma, which has lasted more than 20 months.
Collapse
Affiliation(s)
- Jibing Chen
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China, ;
| | - Youyong Lv
- Beijing Cancer Hospital of Peking University, Beijing 100142, China
| | - Feng Mu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China, ;
| | - Kecheng Xu
- Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China, ;
| |
Collapse
|
30
|
Huang J, Liang X, Xuan Y, Geng C, Li Y, Lu H, Qu S, Mei X, Chen H, Yu T, Sun N, Rao J, Wang J, Zhang W, Chen Y, Liao S, Jiang H, Liu X, Yang Z, Mu F, Gao S. Erratum to: A reference human genome dataset of the BGISEQ-500 sequencer. Gigascience 2018; 7:5221381. [PMID: 30500904 PMCID: PMC6266704 DOI: 10.1093/gigascience/giy144] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Jie Huang
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| | | | - Yuankai Xuan
- State Food and Drug Administration Hubei Center for Medical Equipment Quality Supervision and Testing, Wuhan 430000, P. R. China
| | | | - Yuxiang Li
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Haorong Lu
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Shoufang Qu
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| | - Xianglin Mei
- State Food and Drug Administration Hubei Center for Medical Equipment Quality Supervision and Testing, Wuhan 430000, P. R. China
| | - Hongbo Chen
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| | - Ting Yu
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| | - Nan Sun
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| | - Junhua Rao
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | | | | | - Ying Chen
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Sha Liao
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Hui Jiang
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Xin Liu
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Zhaopeng Yang
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| | - Feng Mu
- BGI-Shenzhen, Shenzhen 518083, P. R. China
| | - Shangxian Gao
- National Institutes for food and drug Control (NIFDC), Beijing 100050, P. R. China
| |
Collapse
|
31
|
Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 2018; 181:147-154. [PMID: 30120887 PMCID: PMC7379487 DOI: 10.1111/bjd.17101] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/13/2018] [Indexed: 12/02/2022]
Abstract
Background Hidradenitis suppurativa (HS), a chronic cutaneous disease, can negatively affect work life. Objectives This retrospective cohort study evaluates the indirect burden among employed patients with HS in the U.S.A. Methods Newly diagnosed and general patients with HS, who were employees (age 18–64 years) from a large claims database (Q1 1999 to Q1 2015), were matched 1 : 5 to controls. Income growth and risk of leaving the workforce were assessed among the newly diagnosed HS and control cohorts in the 5‐year study period. Income, work loss days and indirect costs (absenteeism and disability) were assessed among the general HS and control cohorts in the 1‐year study period. Results Newly diagnosed (n = 1003, mean age 39·5 years, 66·3% female) and general patients with HS (n = 1204, mean age 39·9 years, 69·1% female) were matched to 5015 and 6020 controls, respectively. Newly diagnosed patients with HS had significantly slower income growth ($324 per year) and higher risk of leaving the workforce (adjusted hazard ratio 1·65, 95% confidence interval 1·45–1·88) compared with controls (all P < 0·05). General patients with HS had more total days of work loss (18·4 vs. 7·7), higher annual total indirect costs ($2925 vs. $1483) and lower annual income ($54 925 vs. $62 357) than controls (all P < 0·001). Conclusions Patients with newly diagnosed HS and general patients with HS experienced a greater indirect burden than matched controls. What's already known about this topic? Hidradenitis suppurativa (HS), a chronic inflammatory disease, can negatively affect work life.
What does this study add? This retrospective claims analysis found that HS is associated with high indirect burden, in terms of slower income growth, higher risk of leaving the workforce and higher indirect costs. These results indicate that patients with HS have unmet disease management needs.
Linked Editorial: Zouboulis. Br J Dermatol 2019; 181:7–8. Plain language summary available online Respond to this article
Collapse
Affiliation(s)
- T Tzellos
- Department of Dermatology, Faculty of Health Sciences, University Hospital of North Norway, Tromsø, Norway.,Department of Clinical Medicine, Arctic University, Tromsø, Norway
| | - H Yang
- Analysis Group, Inc., 111 Huntington Ave, Floor 14, Boston, MA, 02199, U.S.A
| | - F Mu
- Analysis Group, Inc., 111 Huntington Ave, Floor 14, Boston, MA, 02199, U.S.A
| | - B Calimlim
- AbbVie, Inc., 1 N. Waukegan Road, North Chicago, IL, 60064, U.S.A
| | - J Signorovitch
- Analysis Group, Inc., 111 Huntington Ave, Floor 14, Boston, MA, 02199, U.S.A
| |
Collapse
|
32
|
Yang Y, Qin Z, Du D, Wu Y, Qiu S, Mu F, Xu K, Chen J. Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer. Cardiovasc Intervent Radiol 2018; 42:48-59. [PMID: 30151798 PMCID: PMC6267679 DOI: 10.1007/s00270-018-2069-y] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Accepted: 08/21/2018] [Indexed: 01/10/2023]
Abstract
Purpose This study aimed to investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer. Materials and Methods Between October 2015 and December 2016, 40 patients were enrolled and randomly allocated to either the IRE group (n = 22) or the IRE–NK group (n = 18). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, CA 19-9, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed. Results Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (PFS 15.1 vs. 10.6 months, P < 0.05, OS 17.9 vs. 23.2 months, P < 0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status. Conclusion Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to confirm these conclusions. Electronic supplementary material The online version of this article (10.1007/s00270-018-2069-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yumei Yang
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 of SunGang West Road, FuTian, Shenzhen, 518035, China
| | - Zilin Qin
- Chongqing Health Service Center, Chongqing, 400020, China
| | - Duanming Du
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 of SunGang West Road, FuTian, Shenzhen, 518035, China.
| | - Yumin Wu
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 of SunGang West Road, FuTian, Shenzhen, 518035, China
| | - Shuibo Qiu
- Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 of SunGang West Road, FuTian, Shenzhen, 518035, China
| | - Feng Mu
- Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
| | | | - Jibing Chen
- Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, 510665, China.
- Fuda Cancer Institute, Guangzhou, China.
| |
Collapse
|
33
|
Huang J, Liang X, Xuan Y, Geng C, Li Y, Lu H, Qu S, Mei X, Chen H, Yu T, Sun N, Rao J, Wang J, Zhang W, Chen Y, Liao S, Jiang H, Liu X, Yang Z, Mu F, Gao S. A reference human genome dataset of the BGISEQ-500 sequencer. Gigascience 2018; 6:1-9. [PMID: 28379488 PMCID: PMC5467036 DOI: 10.1093/gigascience/gix024] [Citation(s) in RCA: 182] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Accepted: 03/28/2017] [Indexed: 12/30/2022] Open
Abstract
Background BGISEQ-500 is a new desktop sequencer developed by BGI. Using DNA nanoball and combinational probe anchor synthesis developed from Complete Genomics™ sequencing technologies, it generates short reads at a large scale. Here, we present the first human whole-genome sequencing dataset of BGISEQ-500. The dataset was generated by sequencing the widely used cell line HG001 (NA12878) in two sequencing runs of paired-end 50 bp (PE50) and two sequencing runs of paired-end 100 bp (PE100). We also include examples of the raw images from the sequencer for reference. Finally, we identified variations using this dataset, estimated the accuracy of the variations, and compared to that of the variations identified from similar amounts of publicly available HiSeq2500 data. We found similar single nucleotide polymorphism (SNP) detection accuracy for the BGISEQ-500 PE100 data (false positive rate [FPR] = 0.00020%, sensitivity = 96.20%) compared to the PE150 HiSeq2500 data (FPR = 0.00017%, sensitivity = 96.60%) better SNP detection accuracy than the PE50 data (FPR = 0.0006%, sensitivity = 94.15%). But for insertions and deletions (indels), we found lower accuracy for BGISEQ-500 data (FPR = 0.00069% and 0.00067% for PE100 and PE50 respectively, sensitivity = 88.52% and 70.93%) than the HiSeq2500 data (FPR = 0.00032%, sensitivity = 96.28%). Our dataset can serve as the reference dataset, providing basic information not just for future development, but also for all research and applications based on the new sequencing platform.
Collapse
Affiliation(s)
- Jie Huang
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| | - Xinming Liang
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Yuankai Xuan
- State Food and Drug Administration Hubei Center for Medical Equipment Quality Supervision and Testing, 24-9, Zhongbei East Road, Wuhan, Hubei Province, 430000, P. R. China
| | - Chunyu Geng
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Yuxiang Li
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Haorong Lu
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Shoufang Qu
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| | - Xianglin Mei
- State Food and Drug Administration Hubei Center for Medical Equipment Quality Supervision and Testing, 24-9, Zhongbei East Road, Wuhan, Hubei Province, 430000, P. R. China
| | - Hongbo Chen
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| | - Ting Yu
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| | - Nan Sun
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| | - Junhua Rao
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Jiahao Wang
- BGI-Qingdao, Tuanjie Rd., Huangdao District, Qingdao, Shandong Province, 266555, P. R. China
| | - Wenwei Zhang
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Ying Chen
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Sha Liao
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Hui Jiang
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Xin Liu
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Zhaopeng Yang
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| | - Feng Mu
- BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong Province, 518083, P. R. China
| | - Shangxian Gao
- National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing 10050, P. R. China
| |
Collapse
|
34
|
Patch AM, Nones K, Kazakoff SH, Newell F, Wood S, Leonard C, Holmes O, Xu Q, Addala V, Creaney J, Robinson BW, Fu S, Geng C, Li T, Zhang W, Liang X, Rao J, Wang J, Tian M, Zhao Y, Teng F, Gou H, Yang B, Jiang H, Mu F, Pearson JV, Waddell N. Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. PLoS One 2018; 13:e0190264. [PMID: 29320538 PMCID: PMC5761881 DOI: 10.1371/journal.pone.0190264] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2017] [Accepted: 12/11/2017] [Indexed: 01/01/2023] Open
Abstract
Technological innovation and increased affordability have contributed to the widespread adoption of genome sequencing technologies in biomedical research. In particular large cancer research consortia have embraced next generation sequencing, and have used the technology to define the somatic mutation landscape of multiple cancer types. These studies have primarily utilised the Illumina HiSeq platforms. In this study we performed whole genome sequencing of three malignant pleural mesothelioma and matched normal samples using a new platform, the BGISEQ-500, and compared the results obtained with Illumina HiSeq X Ten. Germline and somatic, single nucleotide variants and small insertions or deletions were independently identified from data aligned human genome reference. The BGISEQ-500 and HiSeq X Ten platforms showed high concordance for germline calls with genotypes from SNP arrays (>99%). The germline and somatic single nucleotide variants identified in both sequencing platforms were highly concordant (86% and 72% respectively). These results indicate the potential applicability of the BGISEQ-500 platform for the identification of somatic and germline single nucleotide variants by whole genome sequencing. The BGISEQ-500 datasets described here represent the first publicly-available cancer genome sequencing performed using this platform.
Collapse
Affiliation(s)
- Ann-Marie Patch
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Katia Nones
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Stephen H. Kazakoff
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Felicity Newell
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Scott Wood
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Conrad Leonard
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Oliver Holmes
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Qinying Xu
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Venkateswar Addala
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Jenette Creaney
- National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia
- Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | - Bruce W. Robinson
- National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia
- Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | | | | | - Tong Li
- BGI, BGI-Shenzhen, Shenzhen, China
| | | | | | | | | | | | | | - Fei Teng
- BGI, BGI-Shenzhen, Shenzhen, China
| | | | | | | | - Feng Mu
- BGI, BGI-Shenzhen, Shenzhen, China
| | - John V. Pearson
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Nicola Waddell
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- * E-mail:
| |
Collapse
|
35
|
Ma J, Wang Y, Wang W, Dong Y, Xu C, Zhou A, Xu Z, Wu Z, Tang X, Chen F, Yin Y, Wang W, Yan M, Zhang W, Mu F, Yang H. Validation of combinatorial probe-anchor ligation-based sequencing as non-invasive prenatal test for trisomy at a central laboratory. Ultrasound Obstet Gynecol 2017; 50:49-57. [PMID: 27363706 DOI: 10.1002/uog.16010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 06/14/2016] [Accepted: 06/23/2016] [Indexed: 06/06/2023]
Abstract
OBJECTIVE To evaluate the clinical validity of a new ultrahigh-throughput non-invasive prenatal test (NIPT) based on combinatorial probe-anchor ligation (cPAL) sequencing of cell-free fetal DNA (cffDNA) using centralized testing. METHODS Maternal plasma samples were obtained from 10 594 singleton pregnancies in high-risk populations at 20 centers in China, including 8155 that were collected retrospectively and 2439 prospectively. Fetal outcome data and karyotyping results were documented as gold standard and were double blinded during NIPT. The clinical performance of the ultrahigh-throughput sequencing method, cPAL, for NIPT was validated by evaluating its sensitivity, specificity and positive predictive value (PPV) in detecting trisomies 21, 18 and 13 as the centralized testing mode in the reference laboratory. To ensure stable and reproducible performance of centralized cPAL-based NIPT in detecting trisomies, a series of quality-control systems, including sequencing of two sets of artificial samples, were employed and evaluated. RESULTS Ten prospective cases were excluded from the study because of incomplete clinical data. Four prospective samples failed to generate a NIPT result due to assay failure, presenting a failure rate of 0.16% (4/2429). A total of 168 retrospective cases and 47 prospective cases had a positive NIPT result for trisomy, giving respective positive rates of 2.06% and 1.94%. Four false-positive and no false-positive cases were observed in the retrospective and prospective groups, respectively, resulting in PPV of 97.62% (95% CI, 94.02-99.35%) and 100% (95% CI, 92.45-100%), respectively. In the retrospective group, sensitivity and specificity were, respectively, 100% (95% CI, 97.07-100%) and 99.98% (95% CI, 99.94-100%) for trisomy 21, 100% (95% CI, 97.75-100%) and 99.98% (95% CI, 99.94-100%) for trisomy 18, and 100% (95% CI, 15.81-100%) and 100% (95% CI, 99.95-100%) for trisomy 13. In the prospective group, sensitivity and specificity were, respectively, 100% (95% CI, 90.75-100%) and 100% (95% CI, 99.85-100%) for trisomy 21, 100% (95% CI, 63.06-100%) and 100% (95% CI, 99.85-100%) for trisomy 18, and 100% (95% CI, 2.50-100%) and 100% (95% CI, 99.85-100%) for trisomy 13. CONCLUSION In this multicenter study with a full quality-control system, NIPT by centralized cPAL-based testing showed high stability and performance comparable to those of previous validation studies in high-risk populations. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- J Ma
- Peking University First Hospital, Beijing, PR China
| | - Y Wang
- BGI-Shenzhen, Shenzhen, PR China
| | - W Wang
- Hubei Maternal and Child Health Hospital, Wuhan, PR China
| | - Y Dong
- Southwest Hospital, The Third Military Medical University, Chongqing, PR China
| | - C Xu
- Women's Hospital School of Medicine Zhejiang University, Hangzhou, PR China
| | - A Zhou
- Wuhan Medical Care Center for Women and Children, Wuhan, PR China
| | - Z Xu
- Nanjing Maternal and Child Health Hospital, Nanjing, PR China
| | - Z Wu
- Guiyang Maternal and Child Health Hospital, Guiyang, PR China
| | - X Tang
- First People's Hospital of Yunnan Province, Kunming, PR China
| | - F Chen
- BGI-Shenzhen, Shenzhen, PR China
| | - Y Yin
- BGI Genomics Co., Ltd, Shenzhen, PR China
| | - W Wang
- BGI Genomics Co., Ltd, Shenzhen, PR China
| | - M Yan
- BGI-Manufacture, Shenzhen, PR China
| | - W Zhang
- BGI-Manufacture, Shenzhen, PR China
| | - F Mu
- BGI-Manufacture, Shenzhen, PR China
- BGI-Wuhan, Wuhan, PR China
| | - H Yang
- Peking University First Hospital, Beijing, PR China
| |
Collapse
|
36
|
Abstract
OBJECTIVE The objective of this study was to estimate the acute healthcare costs of ischemic stroke during hospitalization and the quarterly all-cause healthcare costs for the first year after discharge by discharge status. METHODS Adult patients with a hospitalization with a diagnosis of ischemic stroke (ICD-9-CM: 434.xx or 436.xx) between 1 January 2006 and 31 March 2015 were identified from a large US commercial claims database. Patients were classified into three cohorts based on their discharge status from the first stroke hospitalization, i.e. dead at discharge, discharged with disability, or discharged without disability. Third-party (medical and pharmacy) and out-of-pocket costs were adjusted to 2015 USD. RESULTS A total of 7919 patients dead at discharge, 45,695 patients discharged with disability, and 153,778 patients discharged without disability were included in this analysis. The overall average age was 59.7 years and 52.3% were male. During hospitalization, mean total costs (third-party and out-of-pocket) were $68,370 for patients dead at discharge, $73,903 for patients discharged with disability, and $24,448 for patients discharged without disability (p < .001 for each pairwise comparison); mean third-party costs were $63,605 for patients dead at discharge, $67,861 for patients discharged with disability and $19,267 for patients discharged without disability (p < .001 for each pairwise comparison). During the first year after discharge, mean total costs for patients discharged with disability vs. without disability were $46,850 vs. $30,132 (p < .001). Mean third-party costs for patients discharged with disability vs. without disability were $19,116 vs. $10,976 during the first quarter after discharge, $10,236 vs. $6926 during the second quarter, $8241 vs. $5810 during the third quarter, and $6875 vs. $5292 during the fourth quarter (p < .001 for each quarter). CONCLUSION The results demonstrated the high economic burden of ischemic stroke, especially among patients discharged with disability with the highest costs incurred during the inpatient stays.
Collapse
Affiliation(s)
- F Mu
- a Analysis Group Inc. , Boston , MA , USA
| | - D Hurley
- b HUTH Global LLC , Seattle , WA , USA
| | - K A Betts
- a Analysis Group Inc. , Boston , MA , USA
| | | | - M Paschoalin
- c Genentech Inc. , South San Francisco , CA , USA
| | - C Kelley
- a Analysis Group Inc. , Boston , MA , USA
| | - E Q Wu
- a Analysis Group Inc. , Boston , MA , USA
| |
Collapse
|
37
|
Shi J, Li Y, Liang S, Zeng J, Liu G, Mu F, Li H, Chen J, Lin M, Sheng S, Zhang H, Liu T, Niu L. Circulating tumour cells as biomarkers for evaluating cryosurgery on unresectable hepatocellular carcinoma. Oncol Rep 2016; 36:1845-51. [PMID: 27573435 DOI: 10.3892/or.2016.5050] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 03/30/2016] [Indexed: 11/06/2022] Open
Abstract
We evaluated the efficacy of pre-cryosurgery and post-cryosurgery circulating tumour cells (CTCs) as biomarkers for unresectable hepatocellular carcinoma (HCC). Real‑time qPCR was used to detect potential biomarker genes in CTCs, and magnetic-activated cell sorting (MACS) and fluorescence‑activated cell sorting (FACS) was performed on 47 patients with hepatocellular cancer who underwent cryosurgery. CTCs in the 47 patients were assessed 1 day before cryosurgery, and 7 and 30 days after cryosurgery. The number of CTCs was 17.70±5.725, 14.64±6.761 and 10.28±5.598, respectively, and this decreased significantly over time (P<0.01). ΔCt values for MAGE-3, survivin and carcinoembryonic antigen (CEA) were elevated significantly compared with those obtained before cryosurgery; 2-ΔΔCt values were <1 before cryosurgery, and were 0.63±1.56, 0.21±0.22 and 0.22±0.34 for MAGE-3, survivin and CEA, respectively, at 7 days after treatment. At 30 days after treatment, 2-ΔΔCt values for MAGE-3, survivin and CEA were 0.24±0.82, 0.03±0.07 and 0.02±0.08, indicating that gene expression in CTCs significantly decreased over time (P<0.01). CTCs were useful biomarkers for evaluating the efficacy of cryosurgery on unresectable HCC.
Collapse
Affiliation(s)
- Jian Shi
- Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
| | - Yuan Li
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Shuzhen Liang
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Jianying Zeng
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Guifeng Liu
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Feng Mu
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Haibo Li
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Jibing Chen
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Mao Lin
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| | - Shihou Sheng
- Department of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
| | - Huaiyu Zhang
- Department of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
| | - Tongjun Liu
- Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
| | - Lizhi Niu
- Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou Fuda Cancer Institute, Guangzhou, Guangdong 510665, P.R. China
| |
Collapse
|
38
|
Shi J, Li Y, Liang S, Zeng J, Liu G, Mu F, Li H, Chen J, Liu T, Niu L. Analysis of circulating tumor cells in colorectal cancer liver metastasis patients before and after cryosurgery. Cancer Biol Ther 2016; 17:935-42. [PMID: 27415969 PMCID: PMC5036405 DOI: 10.1080/15384047.2016.1210731] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
In this study, we determined the number of peripheral blood circulating tumor cells (CTCs) pre- and post-cryosurgery in patients with colorectal cancer liver metastasis as a reference for understanding the relevance of any changes to the efficacy of cryosurgery. CTC numbers and CTC-related gene expression were measured in the peripheral blood of 55 patients with colorectal liver metastasis at 1 day before and 7 and 30 d after cryoablation using magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS) combined with real-time quantitative PCR (RT-qPCR). The number of CTCs decreased significantly with postoperative time (P < 0.01). Delta cycle threshold values for the CTC-related genes CEA, Ep-CAM, CK18 and CK19 increased significantly after cryoablation. Furthermore, the expression of CEA, Ep-CAM, CK18 and CK19 decreased significantly with time after cryoablation (P < 0.01). RT-qPCR and FACS combined with MACS has significant diagnostic and prognostic value for evaluating the efficacy of cryosurgery in patients with advanced colorectal cancer.
Collapse
Affiliation(s)
- Jian Shi
- a Department of General Surgery , The Second Hospital of Jilin University , Changchun , Jilin , China
| | - Yuan Li
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Shuzhen Liang
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Jianying Zeng
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Guifeng Liu
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Feng Mu
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Haibo Li
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Jibing Chen
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| | - Tongjun Liu
- a Department of General Surgery , The Second Hospital of Jilin University , Changchun , Jilin , China
| | - Lizhi Niu
- b Fuda Cancer Hospital , Jinan University School of Medicine, Guangzhou Fuda Cancer Institute , Guangzhou , Guangdong , China
| |
Collapse
|
39
|
Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S, Liu D, Ye X, Ye M, Yang J, Shao L, Pan H, Lu N, Yu Y, Liu L, Li J, Huang L, Tang H, Deng Q, Zheng Y, Peng L, Liu G, Gu X, He P, Gu Y, Lin W, He H, Xie G, Liang H, An N, Wang H, Teixeira M, Vieira J, Liang W, Zhao X, Peng Z, Mu F, Zhang X, Xu X, Yang H, Kristiansen K, Wang J, Zhong N, Wang J, Pan-Hammarström Q, He J. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun 2015; 6:10131. [PMID: 26647728 PMCID: PMC4682110 DOI: 10.1038/ncomms10131] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 11/06/2015] [Indexed: 01/04/2023] Open
Abstract
The landscape of genetic alterations in lung adenocarcinoma derived from Asian patients is largely uncharacterized. Here we present an integrated genomic and transcriptomic analysis of 335 primary lung adenocarcinomas and 35 corresponding lymph node metastases from Chinese patients. Altogether 13 significantly mutated genes are identified, including the most commonly mutated gene TP53 and novel mutation targets such as RHPN2, GLI3 and MRC2. TP53 mutations are furthermore significantly enriched in tumours from patients harbouring metastases. Genes regulating cytoskeleton remodelling processes are also frequently altered, especially in metastatic samples, of which the high expression level of IQGAP3 is identified as a marker for poor prognosis. Our study represents the first large-scale sequencing effort on lung adenocarcinoma in Asian patients and provides a comprehensive mutational landscape for both primary and metastatic tumours. This may thus form a basis for personalized medical care and shed light on the molecular pathogenesis of metastatic lung adenocarcinoma. Despite lung adenocarcinoma having a high global mortality, the genetic mutations present in Asian patients are uncharacterized. Here the authors use genomic and transcriptomic analysis to identify thirteen significantly affected genes, including RHPN2, GLI3, MRC2, TP53 and IQGAP3.
Collapse
Affiliation(s)
- Kui Wu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.,Department of Biology, University of Copenhagen, DK-2200 Copenhagen N, Denmark
| | - Xin Zhang
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| | - Fuqiang Li
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Dakai Xiao
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Yong Hou
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Biology, University of Copenhagen, DK-2200 Copenhagen N, Denmark
| | - Shida Zhu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Biology, University of Copenhagen, DK-2200 Copenhagen N, Denmark
| | - Dongbing Liu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Xiaofei Ye
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Laboratory of Medicine, Karolinska Institutet, Stockholm 14186, Sweden
| | - Mingzhi Ye
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Guangzhou Key Laboratory of Cancer Trans-Omics Research, BGI-Guangzhou, Guangzhou 510006, China
| | - Jie Yang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Libin Shao
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Hui Pan
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Na Lu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Yuan Yu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Liping Liu
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Jin Li
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Liyan Huang
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China
| | - Hailing Tang
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China
| | - Qiuhua Deng
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Yue Zheng
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Lihua Peng
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Geng Liu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Xia Gu
- Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Ping He
- Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Yingying Gu
- Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Weixuan Lin
- Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Huiming He
- Research Center for Translational Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Guoyun Xie
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Han Liang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Na An
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Hui Wang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Manuel Teixeira
- Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal
| | - Joana Vieira
- Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal
| | - Wenhua Liang
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| | - Xin Zhao
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Zhiyu Peng
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Guangzhou Key Laboratory of Cancer Trans-Omics Research, BGI-Guangzhou, Guangzhou 510006, China
| | - Feng Mu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,BGI-Wuhan, Wuhan 430075, China
| | - Xiuqing Zhang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Guangzhou Key Laboratory of Cancer Trans-Omics Research, BGI-Guangzhou, Guangzhou 510006, China
| | - Xun Xu
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Huanming Yang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,James D. Watson Institute of Genome Sciences, Zhejiang University, Hangzhou 310058, China
| | - Karsten Kristiansen
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Jian Wang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,James D. Watson Institute of Genome Sciences, Zhejiang University, Hangzhou 310058, China
| | - Nanshan Zhong
- Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| | - Jun Wang
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Biology, University of Copenhagen, DK-2200 Copenhagen N, Denmark
| | - Qiang Pan-Hammarström
- BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China.,Department of Laboratory of Medicine, Karolinska Institutet, Stockholm 14186, Sweden
| | - Jianxing He
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.,Guangzhou Institute of Respiratory Disease &State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.,National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
| |
Collapse
|
40
|
Mu F, Jing Y, Qin N, Zhu HY, Liu DH, Yuan SG, Xu RF. Novel Polymorphisms of Adrenergic, Alpha-1B-, Receptor and Peroxisome Proliferator-activated Receptor Gamma, Coactivator 1 Beta Genes and Their Association with Egg Production Traits in Local Chinese Dagu Hens. Asian-Australas J Anim Sci 2015; 29:1256-64. [PMID: 26954135 PMCID: PMC5003985 DOI: 10.5713/ajas.15.0794] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Revised: 10/22/2015] [Accepted: 11/24/2015] [Indexed: 12/17/2022]
Abstract
Adrenergic, alpha-1B-, receptor (ADRA1B) and peroxisome proliferator-activated receptor gamma, coactivator 1 beta (PPARGC1B) genes are involved in regulation of hen ovarian development. In this study, these two genes were investigated as possible molecular markers associated with hen-housed egg production, egg weight (EW) and body weight in Chinese Dagu hens. Samples were analyzed using the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique, followed by sequencing analysis. Two novel single nucleotide polymorphisms (SNPs) were identified within the candidate genes. Among them, an A/G transition at base position 1915 in exon 2 of ADRA1B gene and a T/C mutation at base position 6146 in the 3′-untranslated region (UTR) of PPARGC1B gene were found to be polymorphic and named SNP A1915G and T6146C, respectively. The SNP A1915G (ADRA1B) leads to a non-synonymous substitution (aspartic acid 489-to-glycine). The 360 birds from the Dagu population were divided into genotypes AA and AG, allele A was found to be present at a higher frequency. Furthermore, the AG genotype correlated with significantly higher hen-housed egg production (HHEP) at 30, 43, 57, and 66 wks of age and with a higher EW at 30 and 43 wks (p<0.05). For the SNP T6146C (PPARGC1B), the hens were typed into TT and TC genotypes, with the T allele shown to be dominant. The TC genotype was also markedly correlated with higher HHEP at 57 and 66 wks of age and EW at 30 and 43 wks (p<0.05). Moreover, four haplotypes were reconstructed based on these two SNPs, with the AGTC haplotype found to be associated with the highest HHEP at 30 to 66 wks of age and with higher EW at 30 and 43 wks (p<0.05). Collectively, the two SNPs identified in this study might be used as potential genetic molecular markers favorable in the improvement of egg productivity in chicken breeding.
Collapse
Affiliation(s)
- F Mu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China
| | - Y Jing
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China
| | - N Qin
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China
| | - H Y Zhu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China
| | - D H Liu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China
| | - S G Yuan
- Jilin Grain Group Agriculture and Livestock Co., Ltd., Changchun 130062, Jilin, China
| | - R F Xu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China
| |
Collapse
|
41
|
Lucas J, Lack C, Wagner B, Kuremsky J, Mu F, Chan M, Sweeney A, Maldjian J, Whitlow C. A Comprehensive Assessment of Radiographic, Clinical, and Treatment Related Risk Factors for Metastasis Related Intracranial Hemorrhage in Metastatic Melanoma Following Radiation Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.831] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Qin N, Liu Q, Zhang YY, Fan XC, Xu XX, Lv ZC, Wei ML, Jing Y, Mu F, Xu RF. Association of novel polymorphisms of forkhead box L2 and growth differentiation factor-9 genes with egg production traits in local Chinese Dagu hens. Poult Sci 2015; 94:88-95. [PMID: 25577797 DOI: 10.3382/ps/peu023] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Transcription factor forkhead box L2 (FOXL2) and growth differentiation factor-9 (GDF9) genes have critical roles in the regulation of hen ovarian development. In the present study, these genes were explored as possible molecular markers associated with BW, hen-housed egg production, and egg weight in Chinese Dagu hens. Samples were analyzed using the PCR-single strand conformation polymorphism (PCR-SSCP) technique followed by sequencing analysis, and two novel single nucleotide polymorphisms (SNPs) were identified within these candidate genes. Among them, an A/G transition at base position 238 in the coding region of the FOXL2 gene and a G/T transversion at base position 1609 in exon 2 of the GDF9 gene were found to be polymorphic and named SNPs A238G and G1609T, respectively. The SNP A238G (FOXL2) leads to a nonsynonymous substitution (isoleucine77-to-valine), and when the 360 Dagu hen samples were divided into genotypes AA and AB, allele A was found to be present at a higher frequency. Furthermore, the AA genotype correlated with significantly higher hen-housed egg production at 30, 43, 57, and 66 wk of age and with a higher egg weight at 43 wk (P<0.05). For the SNP G1609T (GDF9), the hens were typed into TT and TC genotypes, with the T allele shown to be dominant. The TC genotype was also markedly correlated with higher hen-housed egg production and a higher egg weight (P<0.05). Moreover, four haplotypes were reconstructed based on these two SNPs, with the AATC haplotype found to be correlated with the highest hen-housed egg production at 30 to 66 wk of age and with higher egg weights at 43 wk (P<0.05). Collectively, the two SNPs identified in this study might be used as possible genetic molecular markers to aid in the improvement of egg production traits in chicken breeding.
Collapse
Affiliation(s)
- N Qin
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - Q Liu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - Y Y Zhang
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - X C Fan
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - X X Xu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 130118, Hubei, China
| | - Z C Lv
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - M L Wei
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - Y Jing
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - F Mu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - R F Xu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| |
Collapse
|
43
|
Qin N, Fan XC, Zhang YY, Xu XX, Tyasi TL, Jing Y, Mu F, Wei ML, Xu RF. New insights into implication of the SLIT/ROBO pathway in the prehierarchical follicle development of hen ovary. Poult Sci 2015; 94:2235-46. [PMID: 26188027 DOI: 10.3382/ps/pev185] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2015] [Accepted: 05/19/2015] [Indexed: 01/28/2023] Open
Abstract
The SLIT/Roundabout (ROBO) pathway is involved in follicle development of mammalian ovary, and 2 secreted hormones activin A and inhibin A have potential roles in modulation of the SLIT/ROBO system, but the related actions remain poorly understood in bird. The aims of the present study were to examine the spatial and temporal expression of the SLIT ligand genes (SLIT1, SLIT2, and SLIT3) and their receptor ROBO1, ROBO2, ROBO3, and ROBO4 genes in various-sized prehierarchical follicles during hen ovary development and the effects of activin A and inhibin A on the expression of these genes in the cultured hen follicles. Our result demonstrated that the transcripts of the 3 SLIT genes were highly expressed in the developing follicles and expression patterns of the SLIT transcripts were different from those of ROBO genes detected by real-time quantitative reverse transcriptase PCR. Both SLIT and ROBO transcripts were predominantly expressed in oocytes and granulosa cells from the prehierarchichal follicles examined by in situ hybridization. The localization for SLIT and ROBO proteins was revealed by immunohistochemistry similar to the spatial distribution of their transcript. In cultured follicles (4 to 8 mm in diameter), the expression levels of SLIT and ROBO members are hormonally regulated by activin A (10 ng/mL) and/or inhibin A (20 ng/mL) after treatment for 24 h. However, the expression of only SLIT2, SLIT3, and ROBO3 mRNA presented a directly opposite response to activin A and inhibin A hormones. These results indicate that SLIT/ROBO pathway is implicated in the prehierarchical follicular development of the hen ovary by an intrafollicular autocrine and/or paracrine action, and is influenced by activin A and inhibin A hormones.
Collapse
Affiliation(s)
- N Qin
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - X C Fan
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - Y Y Zhang
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - X X Xu
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - T L Tyasi
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - Y Jing
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - F Mu
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - M L Wei
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| | - R F Xu
- Department of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, Jilin, China
| |
Collapse
|
44
|
Wang L, Yang Y, Song J, Mao L, Wei X, Sun Y, Yang S, Mu F, Wang H, Niu Y. Two novel mutations in the C-terminal region of centrosomal protein 290 (CEP290) result in classic Joubert syndrome. J Child Neurol 2015; 30:772-6. [PMID: 24850569 DOI: 10.1177/0883073814535488] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2013] [Accepted: 04/17/2014] [Indexed: 01/04/2023]
Abstract
Joubert syndrome is a neurologic disorder with a pathognomonic "molar tooth sign" on brain imaging. The purpose of this study was to identify potential mutations in a Chinese patient with Joubert syndrome by targeted massively parallel sequencing. Taking advantage of high-throughput DNA sequencing technologies, 18 Joubert-causing genes of a Chinese patient with classic Joubert syndrome were sequenced at a time, and 2 novel variants in the CEP290 gene (c.7323_7327delAGAAG and c.6012-2A>G) were identified in this patient. Sanger validation showed that 2 variants were inherited from each parents, respectively. Both variants are located in the C-terminal region of the CEP290 protein and are predicted to be deleterious. The results support that the combination of targeted genes enrichment and next-generation sequencing is valuable molecular diagnostic tool and suitable for clinical application.
Collapse
Affiliation(s)
- Lixia Wang
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | | | - Jieping Song
- Prenatal Diagnosis Center, Hubei Maternal and Child Health Hospital, China
| | | | | | - Yan Sun
- BGI-Shenzhen, Shenzhen, China
| | | | | | | | - Yanfeng Niu
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
45
|
Niu L, Zhou L, Xu K, Mu F. The role of cryosurgery in palliative care for cancer. Ann Palliat Med 2015; 2:26-34. [PMID: 25841740 DOI: 10.3978/j.issn.2224-5820.2013.01.09] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Accepted: 01/22/2013] [Indexed: 11/14/2022]
Abstract
Cryosurgery as one of the ablation methods is performed intraoperatively, laparoscopically or percutaneously, is especially adapted for ablation of prostate cancer, liver cancer, lung cancer, kidney cancer, breast cancer, benign fibroadenomas of breast, uterine tumors and neoplasms of soft tissue. Compared with other ablation methods (such as radiofrequency and microwave ablation), cryoablation has several advantages on therapeutic efficacy, imaging guidance and modality.
Collapse
Affiliation(s)
- Lizhi Niu
- Guangzhou Fuda Cancer Hospital, Jinan University School of Medicine, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510305, China.
| | - Liang Zhou
- Department of Oncology, Affiliated Fuda Hospital, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Haizhu District, Guangzhou 510305, China
| | - Kecheng Xu
- Department of Oncology, Affiliated Fuda Hospital, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Haizhu District, Guangzhou 510305, China
| | - Feng Mu
- Department of Oncology, Affiliated Fuda Hospital, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Haizhu District, Guangzhou 510305, China
| |
Collapse
|
46
|
Lin M, Li SY, Xu KC, Liu ZP, Mu F, Yuan YY, Wang XH, Chen JB, Li Q. Safety and efficacy study of lung cancer stem cell vaccine. Immunol Res 2015; 62:16-22. [DOI: 10.1007/s12026-015-8631-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Yang Y, Mao B, Wang L, Mao L, Zhou A, Cao J, Hu J, Zhou Y, Pan Y, Wei X, Yang S, Mu F, Liu Z. Targeted next generation sequencing reveals a novel intragenic deletion of the LAMA2 gene in a patient with congenital muscular dystrophy. Mol Med Rep 2014; 11:3687-93. [PMID: 25544356 DOI: 10.3892/mmr.2014.3135] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Accepted: 11/14/2014] [Indexed: 11/05/2022] Open
Abstract
Mutations in the LAMA2 gene cause laminin α‑2 (merosin)‑deficient congenital muscular dystrophies, which are autosomal recessive muscle disorders. Laminin α‑2 is widely expressed in the basement membrane of skeletal muscle, the myotendinous junctions and extra‑synaptically at neuromuscular synapses. In the present study, target next‑generation sequencing was used for mutation detection, and polymerase chain reaction (PCR) analysis and Sanger sequencing were used in the identification of small deletions. Subsequently, quantitative PCR (qPCR) was performed to characterize the identified deletion encompassing exon five of the LAMA2 gene. Two causative mutations were identified using target region sequencing which provided the additional information required to facilitate clinical diagnosis. One heterozygous mutation (p. Lys682LysfsX22) was identified and confirmed by Sanger sequencing, and another heterozygous mutation (Exon5del) was found and validated by qPCR. Co‑segregation analysis indicated that the Exon5del mutation originated from the proband's mother and the previously reported frameshift mutation (p. Lys682LysfsX22) was inherited from the proband's father. To the best of our knowledge, the present study was the first to report an entire exon five deletion in the LAMA2 gene.
Collapse
Affiliation(s)
- Yun Yang
- Department of Research and Development, BGI‑Central China, Wuhan East Lake High‑Tech Development Zone, Wuhan, Hubei 430075, P.R. China
| | - Bing Mao
- Department of Neurology, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei 430016, P.R. China
| | - Lixia Wang
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430074, P.R. China
| | - Liangwei Mao
- Department of Research and Development, BGI‑Central China, Wuhan East Lake High‑Tech Development Zone, Wuhan, Hubei 430075, P.R. China
| | - Aifen Zhou
- Department of Obstetrics, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei 430016, P.R. China
| | - Jiangxia Cao
- Department of Obstetrics, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei 430016, P.R. China
| | - Jiasheng Hu
- Department of Neurology, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei 430016, P.R. China
| | - Yan Zhou
- Department of Obstetrics, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei 430016, P.R. China
| | - Yanhong Pan
- Department of Research and Development, BGI‑Shenzhen, Shenzhen, Guangdong 518083, P.R. China
| | - Xiaoming Wei
- Department of Research and Development, BGI‑Shenzhen, Shenzhen, Guangdong 518083, P.R. China
| | - Shuang Yang
- Department of Research and Development, BGI‑Central China, Wuhan East Lake High‑Tech Development Zone, Wuhan, Hubei 430075, P.R. China
| | - Feng Mu
- Department of Research and Development, BGI‑Central China, Wuhan East Lake High‑Tech Development Zone, Wuhan, Hubei 430075, P.R. China
| | - Zhisheng Liu
- Department of Neurology, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei 430016, P.R. China
| |
Collapse
|
48
|
Alnaggar M, Niu L, Li J, Yao F, Wang Y, Zeng J, Ye J, Chen J, Mu F, Xu K. Cryoprotective therapy for huge hepatocellular carcinoma: a study of 14 patients with a single lesion. Cryobiology 2014; 69:457-61. [PMID: 25445461 DOI: 10.1016/j.cryobiol.2014.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 10/03/2014] [Accepted: 10/07/2014] [Indexed: 02/07/2023]
Abstract
Percutaneous cryoablation is a potential cure for hepatocellular carcinoma (HCC). This study reviewed retrospectively clinical data from 14 patients who underwent cryoablation of huge HCC (long diameter >7 cm). The side effects of cryosurgeries and liver function reverse were recorded and compared everyday. All the patients survived cryosurgery and none died before leaving hospital 2 weeks later. Despite liver-protective treatment before cryosurgery, alanine transaminase (ALT) and aspartate transaminase (AST) levels were increased significantly, but returned to preoperative levels 2 weeks post-cryosurgery. Before cryosurgery, mean total bilirubin (T.BIL) and direct bilirubin (D.BIL) levels were normal; 8-10 days after cryosurgery, they increased more than two-fold, but returned to the preoperative level 2 weeks post-cryosurgery. Serum transaminase and bilirubin levels were compared between hepatitis B positive and negative patients. The hepatitis B negative group's AST level increased significantly 1 day post-cryosurgery (mean, 186 U/L) and decreased to the preoperative level at day 14. In the hepatitis B positive group, means transaminase and bilirubin reached peak values at different days post-cryosurgery. Overall, ALT and AST are valuable indicators of liver function impairment following cryosurgery. In patients with hepatitis B virus, close attention to the serum bilirubin level should be paid 8-10 days after cryosurgery. Liver-protective treatment may alleviate liver function impairment caused by cryosurgery of huge HCC.
Collapse
Affiliation(s)
- Mohammed Alnaggar
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, No. 1277 of JieFang Road, Wuhan 430032, China
| | - Lizhi Niu
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Cryosurgery for Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| | - Jialiang Li
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Cryosurgery for Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| | - Fei Yao
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| | - Yuan Wang
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| | - Jianying Zeng
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| | - Jin Ye
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, No. 1277 of JieFang Road, Wuhan 430032, China
| | - Jibing Chen
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Cryosurgery for Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China.
| | - Feng Mu
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Cryosurgery for Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| | - Kecheng Xu
- Fuda Cancer Hospital, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Cryosurgery for Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China
| |
Collapse
|
49
|
Guan Y, Hu H, Peng Y, Gong Y, Yi Y, Shao L, Liu T, Li G, Wang R, Dai P, Bignon YJ, Xiao Z, Yang L, Mu F, Xiao L, Xie Z, Yan W, Xu N, Zhou D, Yi X. Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer 2014; 14:9-18. [DOI: 10.1007/s10689-014-9749-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
50
|
Li J, Wang B, Wang S, Mu F. Effects of hypertonic saline - hydroxyethyl starch and mannitol on serum osmolality, dural tension and hemodynamics in patients undergoing elective neurosurgical procedures. Int J Clin Exp Med 2014; 7:2266-2272. [PMID: 25232419 PMCID: PMC4161579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Accepted: 06/27/2014] [Indexed: 06/03/2023]
Abstract
OBJECTIVE To investigate effect of equal volumes (250 ml) of 7.2% hypertonic saline - 6% hydroxyethyl starch (HS-HES) and 20% mannitol (M) on dural tension, serum osmolality and hemodynamics in patients during elective neurosurgical procedures. MATERIAL AND METHODS Forty ASA I-II patients scheduled for elective neurosurgical supratentorial procedures were randomly assigned to two groups. About 30 min before skull opening, patients received either HS-HES or M at infusion rate 750 ml/h. Dural tension score was used to evaluate the dural tension by neurosurgeons. Serum osmolality was tested at following time points: before, 125 ml infused, 250 ml infused, 30 min and 60 min after infusion. Hemodynamic variables were measured by FloTrac. RESULTS Patients who received HS-HES had a significant decrease in dural tension scores (P < 0.05) and obtained more satisfactory brain relaxation for neurosurgeon (95% vs. 75%). In HS-HES group, the peak of serum osmolality occurred earlier and hyperosmolality lasted for longer time. Transient decrease in mean arterial pressure was observed in M group at 10 min after the start infusion (P < 0.01). Heart rate significantly decreased after HS-HES infusion, whereas no significant changes were observed in M group. In HS-HES group, stroke volume variation significantly decreased from 9.7 ± 3.5 at the initiation of infusion to 6.7 ± 2.4 at 30 min after the infusion and remained decreased more than 60 min while it decreased from 6.8 ± 3.1 to 5.3 ± 1.5 in M group. Moreover, urine output in HS-HES group from initiation to 60 min after the infusion was significantly less than those in M group. CONCLUSION HS-HES might be an alternative to mannitol in treatment of intracranial hypertension.
Collapse
Affiliation(s)
- Jiao Li
- Department of Anesthesiology, Beijing Sanbo Brain Hospital, Capital Medical University Beijing, China
| | - Baoguo Wang
- Department of Anesthesiology, Beijing Sanbo Brain Hospital, Capital Medical University Beijing, China
| | - Shuangyan Wang
- Department of Anesthesiology, Beijing Sanbo Brain Hospital, Capital Medical University Beijing, China
| | - Feng Mu
- Department of Anesthesiology, Beijing Sanbo Brain Hospital, Capital Medical University Beijing, China
| |
Collapse
|